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1.0 Abstract 
Inherited disorders of haemoglobin are the most common monogenic diseases 
in the world. These conditions arise as a result of deletions or point mutations 
affecting the globin genes. Gap polymerase chain reaction (Gap-PCR) is 
commonly used to detect globin gene deletions, however this technique is not 
ideal since it is time consuming and only able to detect known deletions with well-
defined breakpoints. To address these issues an alternative technique called 
Gene Ratio Analysis Copy Enumeration (GRACE) PCR was developed. In 
contrast to Gap-PCR, GRACE-PCR is a rapid, closed tube technique, requiring 
no further hands on time after the initial PCR setup. Furthermore, since it is based 
on copy number determination, GRACE-PCR does not require prior knowledge 
of the breakpoints and can thus be used for the detection of both known and 
novel deletions. GRACE-PCR methods were validated for the most clinically 
significant globin genes, HBA1, HBA2 and HBB.  
The large number of point mutations associated with the HBB gene make gene 
scanning by High Resolution Melting (HRM) PCR a potentially attractive 
diagnostic method. HRM-PCR assays have been previously described, however 
interference from certain Single Nucleotide Polymorphisms (SNPs) limited their 
ability to detect some mutations. Through the use of unlabelled probes and 
primers incorporating universal bases, it was possible to develop a more 
universally applicable HRM-PCR assay that was not affected by SNPs.  
Additionally, a number of examples of two very rare haemoglobins, Hb 
Fontainebleau and Hb Handsworth were encountered during the course of this 
work. Each of these variants had previously been reported in just ten individuals 
worldwide. The behaviour of these two rare variants is described.  
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2.0 General introduction 
2.1 The global importance of inherited disorders of haemoglobin 
Inherited disorders of haemoglobin occur in high frequencies throughout the 
tropics (Figure 1) and are the most common monogenic disorders in the world 
(Weatherall & Clegg 2001; Harteveld & Higgs 2010; Luo & Chui 2016). Recent 
analysis of the thousand genomes project data indicates that 7.4% of people 
have a deleterious mutation of the haemoglobin subunit beta (HBB) gene 
(Carlice-dos-Reis et al. 2017), while the frequency of a-globin gene deletions 
varies from 2-70% and has almost reached fixation in some isolated communities  
(Higgs & Weatherall 2009; Harteveld & Higgs 2010). Mild heterozygous 
expression of these conditions is believed to provide some degree of protection 
against malaria (Flint et al. 1998; Amaratunga & Fairhurst 2014; Elguero et al. 
2015), but the more severe forms cause significant morbidity and mortality 
(Weatherall 2011).  
In recent decades population migrations mean that these conditions are now 
being diagnosed with increasing frequency in geographical locations where they 
were not traditional found (Thein 2005; Giordano 2013; Traeger-Synodinos et al. 
2015) such as the United Kingdom (Old et al. 2000; Henderson et al. 2016), the 
Netherlands (van Zwieten et al. 2014) and Australia (Phylipsen et al. 2010; 
Crighton et al. 2016). Additionally, migration is changing the spectrum of disease 
being encountered. For example, while sickle cell disease is a well-documented 
problem in the United States thalassaemia used to be comparatively rare, but has 
become increasingly common in recent decades (Hoppe 2011; Sayani & 
Kwiatkowski 2015).  
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The World Health Organization (WHO) considers that inherited haemoglobin 
disorders now represent a significant public health problem in 71% of countries 
worldwide and estimates that globally there are approximately 300,000 severely 
affected infants born yearly (Weatherall & Clegg 2001; Modell 2008). 
Consequently, many countries have adopted pre-marital screening programs 
aimed at reducing the incidence of inherited haemoglobin disorders. These 
programs represent major public health initiatives, the success of which is heavily 
dependent on reliable laboratory diagnosis of carriers. Limitations of conventional 
biochemical assays mean that molecular techniques may be required for 
definitive diagnosis of inherited haemoglobin disorders. However, cost effective 
molecular diagnosis can be challenging since the severe forms of these 
conditions may arise as the result of over a thousand mutations affecting three 
different genes. 
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Figure 1: A world map showing the distribution of inherited disorders of haemoglobin. 
Based on WHO data (http://www.who.int/genomics/public/geneticdiseases/en/). 
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2.2 Normal haemoglobin synthesis 
2.2.1 The structure and function of haemoglobin 
Haemoglobin is a tetrahedral molecule composed of four sub-units (Figure 2). 
Each sub-unit consists of a protein called a globin chain and an iron containing 
haem element. Newly synthesized globin chains will naturally fold into a-helical 
structures. Individual globin chains are unstable, but a-globin like chains (globin 
produced from the genes of the a-globin locus) will form stable dimers with b-
globin like chains (globin produced from the genes of the b-globin locus). The 
subsequent association of two dimer pairs results in the formation of a 
haemoglobin molecule (Thom et al. 2013).  
Haemoglobin is synthesized within erythroid precursor cells. During early foetal 
development haemoglobin synthesis occurs initially in the yoke sac and 
subsequently in the liver. As the bone marrow develops it progressively takes 
over this function and is the main site of haemoglobin synthesis by the time of 
birth (Sankaran, Xu & Orkin 2010a).  
The environment inside the red blood cell keeps the iron associated with the 
haem element in a reduced state (Fe2+), which is essential for oxygen binding. 
Haemoglobin will bind oxygen molecules when exposed to a high oxygen partial 
pressure (pO2) and progressively release oxygen as the pO2 falls (Figure 3), thus 
allowing haemoglobin to perform the vital function of transporting oxygen to 
respiring tissues throughout the body (Brittain 2002).  
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Figure 2: The structure of the haemoglobin A (Hb A) molecule. Hb A is the most abundant 
form of haemoglobin in normal adults and consists of 2 a-globin chains (show in red) and 2 b-
globin chains (shown in blue). Each globin chain is wrapped around an iron containing haem unit 
(shown in green). Image by Richard Wheeler 2007 released under the GNU Free Documentation 
License. 
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Figure 3: Haemoglobin oxygen dissociation curves. Haemoglobin takes up oxygen when 
exposed to a high external pO2 and releases it as the pO2 falls resulting in a sigmoid saturation 
curve (black line). The shape of the curve alters according to metabolic activity. During high 
metabolic activity (blue line) falling pH and increased 2.3-diphosphoglycerate (2,3DPG), lower 
oxygen affinity favouring the T state (no oxygen bound). Conversely low metabolic activity (red 
line) increases affinity favouring the R state (oxygen bound). This shifting of the saturation curve 
allows oxygen delivery to be adapted to meet metabolic requirements. 
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2.2.2 The globin genes 
There are eight functional globin genes (Figure 4) as well as several pseudo 
genes. The globin genes are found in two loci, each of which has an associated 
upstream regulatory element.  
The a-globin locus on chromosome 16 (Deisseroth et al. 1977; Mettananda et al. 
2016) contains three of the functional globin genes. Listed in 5’ to 3’ order these 
are Haemoglobin subunit zeta (HBZ), Haemoglobin subunit alpha 2 (HBA2) and 
Haemoglobin subunit alpha 1 (HBA1). Expression of the a-globin locus genes 
requires interaction with four upstream elements called the Multispecies 
Conserved Sequences (MCS), the most important of which is MCS region two 
(Higgs 2013). 
 The remaining five functional globin genes are found in the b-globin locus on 
chromosome 11 (Deisseroth et al. 1978; Noordermeer & de Laat 2008). Listed in 
5’ to 3’ order these are Haemoglobin subunit epsilon 1 (HBE1), Haemoglobin 
subunit gamma 2 (HBG2), Haemoglobin subunit gamma 1 ((HBG1), 
Haemoglobin subunit delta (HBD) and Haemoglobin subunit beta (HBB). An 
upstream regulatory element known as the b-Locus Control Region (b-LCR) is 
required for expression of these genes (Kukreti et al. 2010). 
 
	 18	
 
Figure 4: The distribution of functional globin genes within the a-globin locus and the b-
globin locus.  
The genes are indicated by their Human Genome Organisation (HUGO) Gene Nomenclature 
Committee (HGNC) symbols Haemoglobin subunit zeta (HBZ), Haemoglobin subunit alpha 2 
(HBA2), Haemoglobin subunit alpha 1 (HBA1), Haemoglobin subunit epsilon 1 (HBE1), 
Haemoglobin subunit gamma 2 (HBG2), Haemoglobin subunit gamma 1 (HBG1), Haemoglobin 
subunit delta (HBD) and Haemoglobin subunit beta (HBB). 
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2.2.3 Globin gene switching during development 
Embryonic haemoglobins are formed during early development, these are 
subsequently replaced by foetal haemoglobins, which are in turn replaced by 
adult haemoglobins. The features of these different haemoglobins are 
summarised in Table 1. The changes in haemoglobin that occur during 
development are the result of different globin genes being expressed at different 
developmental stages; a process referred to as globin gene switching. 
The b-globin locus switch from the HBE1 gene to the HBG1 / HBG2 genes is 
termed the primitive to definitive switch and marks the end of production of 
primitive erythrocytes in the yoke sac (Sankaran, Xu & Orkin 2010a). A similar a-
globin locus switch occurs from the HBZ gene to the HBA1 / HBA2 genes 
(Mettananda et al. 2016). There is also a subsequent second b-globin locus 
switch from the HBG1 / HBG2 genes to the HBB gene (Sankaran, Xu & Orkin 
2010a), resulting in the change from foetal to adult haemoglobin. However, this 
second switch is less absolute than the primitive to definitive switch and 
consequently trace amounts of Hb F (a2g2) can be detected in most healthy adults 
(Thein & Menzel 2009). 
The processes controlling the regulation of the globin genes have been the 
subject of intense investigation (Stamatoyannopoulos 2005). This interest stems 
from the assumption that improved understanding of the mechanisms involved 
will provide insights into developmental biology and may lead to therapies for the 
treatment of inherited disorders of haemoglobin (Stamatoyannopoulos 2005; 
Sankaran, Xu & Orkin 2010a). Two main mechanisms control globin gene 
switching, competition for access to the upstream regulatory element (Figure 5) 
and autonomous gene silencing (Figure 6) (Stamatoyannopoulos 2005). 
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Table 1: Embryonic, foetal and adult haemoglobins 
Classification Name Genes (See Figure 3) Proteins Significance 
Embryonic 
Haemoglobins 
Haemoglobin 
Gower I 
HBZ; HBE1 
 
2 x-globin chains 
2 e-globin chains 
(x2e2) 
Early embryonic 
haemoglobin 
produced primarily 
in the yoke sac. 
Haemoglobin 
Gower II 
HBA1 or HBA2; 
HBE1 
2 a-globin chains 
2 e-globin chains 
(a2e2) 
Embryonic 
haemoglobin 
produced in the 
liver. Not present 
after the 18th week 
of gestation. 
Haemoglobin 
Portland 
HBZ; 
HBG1 or HBG2 
2 x-globin chains 
2 g-globin chains 
(x2g2) 
Embryonic 
haemoglobin 
produced in the 
liver. Not present 
after the 18th week 
of gestation. 
Foetal 
Haemoglobin 
Foetal 
Haemoglobin  
 
(Hb F) 
HBA1 or HBA2; 
HBG1 or HBG2 
 
2 a-globin chains 
2 g-globin chains 
(a2g2) 
Hb F typically 
accounts for 
approximately 70% 
of the total 
haemoglobin at 
birth. Within the first 
year of life levels 
normally fall to 
<1%, but Hb F 
continues to be 
present in trace 
amounts.  
Adult 
Haemoglobins 
Haemoglobin 
A 
 
(Hb A) 
HBA1 or HBA2; 
HBB 
2 a-globin chains 
2 b-globin chains 
(a2b2) 
Hb A typically 
accounts for >95% 
of the total 
haemoglobin in 
healthy adults. 
Haemoglobin 
A2  
 
(Hb A2) 
HBA1 or HBA2; 
HBD 
 
2 a-globin chains 
2 d-globin chains 
(a2d2) 
Hb A2 accounts for 
<3.3% of the total 
haemoglobin in 
normal adults. Hb 
A2 has no clinical 
significance, but is 
raised in b-
thalassaemia trait, 
making it a useful 
marker for the 
disease.  
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Figure 5: Globin gene switching is driven by competition for an upstream regulatory 
element – see following page for legend 
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Legend for figure 5 (previous page): Interaction between the gene promoters and an upstream 
regulatory element called the b Locus Control Region (b-LCR) is essential for transcription of the 
b-globin genes (Rooks et al. 2005; Suzuki et al. 2014) and is achieved through the formation of a 
chromatin loop (Tolhuis et al. 2002; Noordermeer & de Laat 2008). The HBE1 gene has a 
competitive advantage due its proximity to the β-LCR and so is the first gene in the locus to be 
transcribed. Autonomous suppression of the HBE1 gene allows the HBG1 and HBG2 genes to 
access the b-LCR resulting a switch from embryonic to foetal haemoglobin. Krupple Like Factor 
1 (KLF1) binds to both the b-LCR and the globin gene promoters and is required for transcription 
(Marongiu et al. 2016). However, the CACCC motif which forms the KLF1 binding site is damaged 
in the HBD gene promoter (Donze et al. 1996). Consequently, after subsequent autonomous 
suppression of the HBG1 and HBG2 genes the HBD gene is only minimally expressed. This 
allows the HBB gene access to the b-LCR resulting in the switch from foetal to adult haemoglobin. 
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Figure 6: The role of autonomous gene silencing in the switch from foetal to adult 
haemoglobin – see following page for legend. 
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Legend for figure 6 (previous page): Access to the upstream b-Locus Control Region (b-LCR) 
is required for globin gene transcription. The HBB gene has a competitive disadvantage due to 
its 3’ position in the b-globin locus and is only transcribed once autonomous silencing of the more 
proximal globin genes has occurred. MYB proto-oncogene protein (MYB) acts as a transcription 
factor for the Nuclear Receptor Subfamily 2 Group C Member 1 gene (NR2C1 also known asTR2) 
and the Nuclear Receptor Subfamily 2 Group C Member 2 gene (NR2C2 also known as TR4) 
(Suzuki et al. 2014). Testicular receptor 4 (TR4) is an important transcription factor (Lin et al. 
2014; Shi et al. 2014) that binds to direct repeat (DR) sequences in the g-globin gene promoters 
(Tanabe et al. 2007). TR4 combines with Testicular Receptor 2 (TR2), DNA methyltransferase 1 
(DMNT1) and Lysine-Specific Histone Demethylase 1 (LSD1) to form the Direct Repeat Erythroid-
Definitive (DRED) complex. The DRED complex suppresses HBG1 / HBG2 transcription (Suzuki 
et al. 2014).  MYB also acts as a transcription factor the Krupple Like Factor 1 gene (KLF1). KFL1 
in turn is required for the transcription of the B Cell CLL/Lymphoma 11A (BCL11A) gene. BCL11A 
has been shown to bind to both the β-LCR and to a region between the HBG1 and HBD genes 
as part of a complex also containing transcription factors GATA1 and Friend of GATA1 (FOG1) 
in association with the Nucleosome Remodelling Deacetylase (NuRD) complex (Sankaran et al. 
2008; Suzuki et al. 2014). Binding BCL11A to these sites further silences transcription of the 
HBG1 and HBG2 (Sankaran, Xu & Orkin 2010b; Bieker 2010). KLF1 is also binds to the HBB 
gene promoter and the b-LCR and plays an important role in stabilizing the chromatin loop 
(Marongiu et al. 2016; Kang et al. 2015). 
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2.3  Inherited haemoglobin disorders 
Inherited haemoglobin disorders can be divided into two main categories 
depending on whether the genetic lesion has a primarily quantitative or qualitative 
effect on globin synthesis. Quantitative genetic defects give rise to 
thalassaemias, while qualitative defects result in the formation of variant 
haemoglobins (Bain 2011). The term haemoglobinopathy is generally accepted 
to encompass both thalassaemias and variant haemoglobins (Bain 2011) and is 
used in this broader sense throughout this thesis.  
To date, 1716 mutations of the globin genes have been described (Hbvar 2017). 
Inheritance of one or more of these mutations gives rise to wide range of possible 
haemoglobinopathies that range in severity from clinically silent through to being 
incompatible with life. 
 
2.3.1 Thalassaemia 
The thalassaemias are a diverse group of conditions resulting from a genetic 
defect that reduces or totally stops the globin chain output from one or more of 
the eight functional globin genes (Figure 4). 
In normal adults Hb A (a2b2) accounts for greater than 95% of the total 
haemoglobin. Consequently, the clinically important forms of thalassaemia are 
those that reduce the production of either a-globin (a-thalassaemia) or b-globin 
(b-thalassaemia). 
 
2.3.1.1 The molecular basis of a-thalassaemia 
The a-globin genes are duplicated (HBA1 and HBA2), thus a normal diploid 
individual will have a total of four functioning a-globin genes (aa/aa). A reduction 
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in expression of one or more of the a-globin genes results in a-thalassaemia 
(Bernini & Harteveld 1998; Piel & Weatherall 2014). Table 2 lists the notations 
commonly used to describe the different a-thalassaemia genotypes.  
When a mutation completely stops a-globin gene expression on a chromosome 
the term a0-thalassaemia is used. a0-Thalassaemia is typically caused by a large 
deletion affecting both the HBA1 and HBA2 genes. Milder mutations can result in 
a chromosome with some residual a-globin gene expression, a condition referred 
to as a+-thalassaemia. a+-Thalassaemia may arise from the deletion of a single 
a-globin gene, or somewhat less commonly from a point mutation in either the 
HBA1 or HBA2 gene (Harteveld & Higgs 2010).  
Although more that 80 point mutations associated with a-thalassaemia have been 
described most are rare (Hbvar 2017). In contrast, deletions of the a-globin genes 
are very common in some populations (Harteveld & Higgs 2010), for example a 
study of 2,000 infants born in the United Arab Emirates found that 46% had one 
or more of the a-globin genes deleted (Baysal 2011).  
Deletions of the a-globin genes arise as a result of unequal crossover events. 
The unequal crossover processes leading to the formation of the two most 
common a+-thalassaemia alleles, -a3.7 and -a4.2 are illustrated in Figure 7. 
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Table 2: Notations used to describe a-thalassaemia genotypes 
Example of notation Description 
aa/aa Wild type with four functional a-globin genes. Each allele containing a normal HBA1 and HBA2 gene.  
-a/aa Deletion of one a-globin gene, indicated by a dash (-). 
--/aa 
Cis deletion of two a-globin genes. Heterozygous for a 
large deletion affecting both the HBA1 and HBA2 
genes. 
-a/-a Trans deletion of two a-globin genes.  
-a4.2/aa 
The optional use of superscript allows the specific 
deletion involved to be identified. In this case the 
common 4.2 Kb deletion.  
-(a)20.5 
The 20.5 Kb deletion removes the whole of the HBA2 
gene and part of the HBA1 gene, indicated by the 
parenthesis.  
aaaAnti 3.7/aa An additional a symbol indicates an additional functional a-globin gene.  
aTa/aa 
The superscript T after the first a symbol indicates the 
presence of a non-deletional thalassaemia mutation in 
the HBA2 gene. 
aaT/aa 
The superscript T after the second a symbol indicates 
the presence of a non-deletional thalassaemia 
mutation in the HBA1 gene. 
aPoly A1a/aa 
Superscript can also be used to identify a specific 
point mutation. In this example, the Poly A1 mutation 
located in the HBA2 gene. 
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Figure 7: A schematic representation of two unequal crossover events affecting the a-
globin gene locus. (A) Unequal crossover results in the effective deletion of 3.7 kb including the 
3’ end of the HBA2 gene and the first two exons of the HBA1 gene. The resulting -a3.7 allele 
contains a single functioning hybrid gene. This process leads also leads to the formation of the 
aaaAnti 3.7 allele with three functioning genes on the opposing DNA strand. (B) A similar unequal 
crossover event results in the effective deletion of 4.2 kb, leading to the formation of the -a4.2 
allele and the corresponding aaaAnti 4.2 allele (Harteveld & Higgs 2010). 
	 29	
2.3.1.2 The molecular basis of b-thalassaemia 
To date 281 mutations of the HBB gene have been described that are associated 
with b-thalassaemia (Hbvar 2017). In contrast to a-thalassaemia which is 
primarily caused by large gene deletions, the majority of b-thalassaemia cases 
are the result of point mutations or small insertions / deletions (indels). When a 
mutation completely stops b-globin production the term b0-thalassaemia is used. 
Mutations that reduce, but do not totally stop HBB gene expression give rise to 
b+-thalassaemia and if the mutation is sufficiently mild to be silent in the 
heterozygous form the term b++-thalassaemia may be applied (Thein 2005).  
Deletions of the HBB gene were once thought to be very rare, but have been 
shown in more recent studies to be somewhat more common than was previously 
believed (Harteveld 2005). Large deletions may also affect other genes from the 
b-globin locus in addition to the HBB gene. The most extreme example being the 
egdb-thalassaemias in which all the b-globin genes are affected. In Group I egdb-
thalassaemia all the genes in the b-globin locus are deleted, while in Group II 
egdb-thalassaemia the deletion does not extend to the HBB gene. Interestingly, 
transcription of the HBB gene is totally halted in Group II egdb-thalassaemia, 
despite the gene and its promoter being left intact.  This is due to the deletion of 
the b-LCR and illustrates in importance of this upstream regulatory element for 
globin gene function (Figures 5 & 6) (Rooks et al. 2005; Noordermeer & de Laat 
2008). 
Non-deletional b-thalassaemia mutations are far more common than HBB gene 
deletions and may reduce b-globin synthesis through several different molecular 
mechanisms, as described in Table 3.  
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Table 3: Molecular mechanisms of non-deletional b-thalassaemia 
Class of mutation Mechanism Severity Examples 
 Transcriptional 
mutations 
Mutations in the promoter 
alter the binding sites for 
transcription factors.  
b+ or b++ HBB:c.-151C>T HBB:c.-138C>A 
Mutations of the or the 5’ 
untranscribed region (UTR) 
result in mild b-
thalassaemia alleles. The 
mechanism is uncertain, 
but may be due to reduced 
capping efficiency. 
b++ HBB:c.-50A>C HBB:c-31C>T 
RNA processing 
mutations 
Genes with mutations at 
the splice junctions are 
transcribed normally, but 
are not spliced into 
functional mRNA. 
b0 HBB:c.92+1G>A HBB:c.315+1G>A 
Mutations affecting the 
consensus splice sequence 
are typically less severe 
that those affecting the 
invariant nucleotides of the 
splice junction.  However, 
they can still greatly reduce 
the amount of functional 
mRNA produced. 
b+ HBB:c.92+5G>C HBB:c.92+6T>C 
Where a mutation results in 
the formation of a cryptic 
splice site both normal and 
aberrant mRNA is 
produced. 
b+ or b++ HBB:c.93-21G>A HBB:c316-106G>C 
Mutations changing the 
AATAAA sequence in the 3’ 
UTR inhibit the 
polyadenylation process. 
b+ or b++ HBB:c.*110T>C HBB:c.*111A>G 
RNA translation 
mutations 
Mutations removing the 
initiation codon prevent 
translation. 
b0 HBB:c.1A>G HBB:c.2T>A 
Mutations that result in a 
nonsense codon lead to the 
formation of a transcript 
that cannot be translated. 
b0 HBB:c.47G>A HBB:c.118C>T 
Mutations causing a 
reading frame shift result in 
mRNA that cannot be 
translated into viable 
globin. 
b0 HBB:c.25_26delAA HBB:c.112delT 
 
(Thein 1998; Thein 2009) 
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2.3.1.3 The clinical significance of thalassaemia 
The clinical manifestations of thalassaemia are highly variable, ranging from 
silent through to life threatening. The terminology used to describe the different 
clinical presentations of the disease is explained in Table 4.  
Normally the a-globin and b-globin are synthesized at the same rate, in 
thalassaemia a reduction of one type of globin leads to an excess of the other. 
Unpaired globin chains accumulate in red cell precursors causing ineffective 
erythropoiesis (Figure 8), this leads to anaemia and interferes with the regulation 
of dietary iron uptake (Figure 9). Consequently, the clinical severity of the disease 
is largely dependent on the degree of globin chain imbalance.  
A mild globin chain imbalance results in a thalassaemia minor phenotype, while 
individuals with a more marked imbalance will have non-transfusion dependent 
thalassaemia (NTDT). The most clinically significant forms of thalassaemia 
normally occur when there is a complete absence of either a-globin or b-globin.  
The severest form of a-thalassaemia is Hb Bart’s hydrops foetalis, where a 
complete absence of a-globin results in the developing foetus being unable to 
produce Hb F and Hb A. Consequently, once the embryonic globin genes are 
silenced the only haemoglobin produced is the non-functional Hb Bart’s (g4). 
Bart’s hydrops foetalis usually causes in foetal death in late pregnancy, although 
intrauterine exchange transfusions may lead to the live birth of infants with a 
thalassaemia major phenotype (Chmait et al. 2015; Pecker et al. 2016). 
Similarly, a complete absence of b-globin typically results in a severe condition 
known as b-thalassaemia major. Infants with b-thalassaemia major usually 
appear normal at birth, but develop profound anaemia within the first year of life 
due to an inability to replace falling levels of Hb F with Hb A.  
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Without blood transfusions life expectancy for a child with thalassaemia major is 
less than five years (Borgna-Pignatti 2010). Under transfusion results in the 
classical appearance of a thalassaemic child; undersized for their age, with 
wasted limbs, extended abdomen, bossing of the skull and hypertrophy of the 
maxillae resulting in exposure of the upper teeth (Cao & Galanello 2010; Bahram 
& Said-Al-Naief 2015). Regular transfusions can increase life expectancy to 10 -
15 years (Telfer 2009), but cause iron overload, which is a major and potentially 
fatal complication of thalassaemia (Figure 9). Access to iron chelation therapy 
reduces the risk of iron overload and may extend life expectancy to 50 years 
(Telfer 2009). Many thalassaemia patients suffer from chronic pain, which seems 
to increase in severity as they age (Lal 2016). An additional complication of b-
thalassaemia major is a thrombotic tendency, which can lead to transient 
ischemic attacks and strokes (Musallam et al. 2012; Karimi et al. 2016). 
Currently, the only cure for thalassaemia is allogeneic haematopoietic stem cell 
transplant (Lucarelli et al. 2012), however this option is only available to patients 
with suitable donors and even then entails a significant risk of morbidity or 
mortality (Cao et al. 2011). Recent advances in the ability to induce 
haematopoietic stem cells from somatic cells, combined with enhancements to 
gene editing technologies may result in new therapeutic approaches becoming 
available in the future (Dever et al. 2016; Ou et al. 2016; Liu et al. 2017).  
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Table 4: Clinical terms used to indicate the severity of thalassaemia 
Clinical term Description 
Silent thalassaemia trait No apparent effect on phenotype.  
Thalassaemia minor 
 
also known as 
 
Thalassaemia trait 
Individuals are largely asymptomatic, but have 
mild haematological abnormalities, including sub-
clinical anaemia and a reduced mean red cell 
volume (MCV). 
Non-transfusion dependent 
thalassaemia (NTDT) 
 
also known as  
 
Thalassaemia intermedia 
Individuals with NTDT are symptomatic and may 
occasionally require blood transfusions, but not 
totally transfusion dependent (Rivella 2015; 
Vichinsky 2015; Saliba & Taher 2016).  
 
Since NTDT is a very broad category, a severity 
index has recently been proposed by an 
international panel of experts (Cappellini et al. 
2016). This system uses weighted scores from 20 
parameters to assess the patient’s haematological 
status, liver function, cardiovascular function and 
other co-morbidities. This results in the 
assignment a severity index ranging from 0 to 52, 
with higher scores representing more severe 
disease. 
Thalassaemia major 
Severely affected individuals who are dependent 
on blood transfusions to maintain a haemoglobin 
level compatible with life.  
Hb Bart’s hydrops foetalis 
Normally incompatible with life, causing foetal 
death in late pregnancy. However, perinatal 
intrauterine exchange transfusions may result in 
live births of infants with a thalassaemia major 
phenotype. 
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Figure 8: Ineffective erythropoiesis in b-thalassaemia – see following page for legend 
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Legend for figure 8 (previous page): During normal erythropoiesis (top panel) erythropoietin 
(EPO) is secreted by the kidneys in response to anaemia. EPO allows Heat Shock Protein 70 
(HSP70) to enter the nucleus of the developing erythroid cells. HPS70 acts as a molecular 
chaperone for GATA1, which is the major regulator of erythropoiesis. When haemoglobin levels 
are adequate, EPO production ceases and HSP70 cannot enter the nucleus. This results in 
GATA1 being inactivated by Caspase-3 and leads to cell death by apoptosis. In b-thalassaemia 
(bottom panel) there is persistent anaemia due the shortage of b-globin chains. Consequently, 
EPO is continuously secreted and the marrow is hyperactive. However, the accumulation of free 
a-globin chains in the developing erythroid cells is toxic and leads to cell death (Sumera et al. 
2015; Arlet et al. 2016). 
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Figure 9: Iron overload in b-thalassaemia – see following page for legend 
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Legend for figure 9 (previous page): Ineffective erythropoiesis results in the release of Growth 
Differentiation Factor 15 (GDF15) and Twisted Granulation 1 (TWSG1). GDF15 and TWSG1 
suppress hepcidin production and consequently lead to chronic increased iron uptake from the 
gut (Tanno et al. 2009; Nienhuis & Nathan 2012; Guimarães et al. 2015). This mechanism 
ultimately leads to iron overload, even in non-transfused b-thalassaemia patients. In transfused 
patients, each unit of packed red cells contains 200 – 250 mg of iron (Ou et al. 2017) which is the 
equivalent of approximately 200 days normal dietary uptake (Nienhuis & Nathan 2012). 
Consequently, transfused patients are particularly susceptible to iron overload. Free iron is toxic 
and accumulates in various tissues including the myocardium. Ultimately, iron overload leads to 
death due to cardiac failure (Auger & Pennell 2016). 
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2.3.1.4 Genotype to phenotype correlation in thalassaemia 
The phenotype of a-thalassaemia depends primarily on the number of functional 
a-globin genes (Table 5) (Higgs & Weatherall 2009; Harteveld & Higgs 2010). 
Loss of one or even two genes has minimal clinical impact, resulting in a silent or 
thalassaemia trait phenotype. The loss of three genes is more significant, 
resulting in a form of NTDT characterized by the presence of variable amounts of 
Hb H (b4) and referred to as Hb H disease (Piel & Weatherall 2014; Turley et al. 
2015). Loss of all four a-globin genes causes Hb Bart’s hydrops foetalis (Piel & 
Weatherall 2014).  
b-Thalassaemia is normally an autosomal recessive disease. Typically, 
inheritance of a single b-thalassaemia allele results in a largely asymptomatic 
trait condition, while inheritance of two b-thalassaemia alleles leads to a 
thalassaemia major phenotype (Thein 2005). However, there are a number of 
exceptions to this generalization that can result in a NTDT or b-thalassaemia 
intermedia phenotype (Table 6). The main modifiers of b-thalassaemia 
phenotype are the severity of the mutations affecting the HBB gene, the number 
of a-globin genes and the ability to produce Hb F (Thein 2005; Lettre 2012; 
Farashi et al. 2015; Mehta et al. 2015; Cebrian et al. 2016; Wienert et al. 2016; 
Hariharan et al. 2017). Thus, the prediction of phenotype from genotype is difficult 
in β-thalassaemia (Nagar et al. 2015).  
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Table 5: Phenotype to genotype correlation in a-thalassaemia 
Phenotype Affected Genes Genotypes Proteins Clinical significance 
Silent 
a-thalassaemia  
HBA1  
or  
HBA2 
-a/aa 
 
aTa/aa 
 
aaT/aa 
a-globin 
slightly 
reduced 
 
b-globin 
normal 
Inheritance of a single a+ allele 
does not normally have any 
observable effect on phenotype. 
a-thalassaemia 
trait 
HBA1 
and or 
HBA2 
--/aa 
 
-a/-a 
 
aPoly Aa/aa 
a-globin 
reduced 
 
b-globin 
normal 
Loss of function of two a-globin 
genes either due to inheritance 
of two a+ alleles or a single a0 
allele normally results in a 
thalassaemia minor phenotype 
with microcytosis and an 
elevated red cell count, but no 
significant anaemia. 
Hb H disease 
 
HBA1 
and 
HBA2 
--/-a 
 
--/aTa 
 
--/aaT 
 
aPoly Aa/aPoly Aa 
a-globin 
significantly 
reduced 
 
b-globin 
normal 
Hb H disease can result from 
either the loss of function of 
three a-globin genes due to 
deletions or point mutations. 
Alternatively, Hb H disease can 
arise from homozygous 
mutations of the HBA2 gene 
poly A tail. These are 
particularly severe point 
mutations that not only render 
the HBA2 gene non-functional, 
but also partially inhibit 
transcription of the downstream 
HBA1 gene (Baysal 2011; Nair 
et al. 2013). Hb H disease 
results in a highly variable 
NTDT phenotype. 
Hb Bart’s 
hydrops 
foetalis 
HBA1 
and 
HBA2 
--/-- 
a-globin 
absent 
 
b-globin 
normal 
Inheritance of two a0 alleles 
results in an inability to produce 
Hb F or Hb A, thus the only 
haemoglobin that can be made 
is the non-functional Hb Bart’s 
(g4). This normally leads to 
foetal death in late pregnancy, 
but intrauterine exchange 
transfusions can result in live 
births of children with a 
thalassaemia major phenotype 
(Chmait et al. 2015). 
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Table 6: Phenotype to genotype correlation for b-Thalassaemia 
Phenotype Affected Genes Genotype Proteins Clinical significance 
Silent 
b-thalassaemia  HBB b
++/b 
a-globin 
normal 
 
b-globin 
reduced 
Inheritance of a single b++ 
allele does not have any 
observable impact on 
phenotype. 
b-thalassaemia 
minor HBB 
b0/b 
 
b+/b 
a-globin 
normal 
 
b-globin 
reduced 
A thalassaemia minor 
phenotype normally results 
from inheritance of a single 
b-thalassaemia allele. 
b-thalassaemia 
intermedia 
(NTDT) 
HBB 
 
and possibly 
 
HBA1/HBA2 
or 
HBG1/HBG2 
b0/b++ 
 
 
b0/b0 and 
HPFH 
 
 
b0/b and 
aaa/aaa 
or 
aa/aaaa 
 
 
b0/b  
(dominant 
mutation) 
a-globin 
normal or 
increased 
 
b-globin 
reduced 
 
g-globin 
normal or 
increased 
 
 
A mild b++ allele or elevated 
levels of Hb F due to 
hereditary persistence of 
foetal haemoglobin (HPFH) 
can ameliorate the severity of 
the phenotype resulting from 
inheritance of two b-
thalassaemia alleles (Thein 
2005).  
  
Alternatively, an excess of a-
globin genes or inheritance 
of a dominant mutation can 
result in a clinically 
significance phenotype even 
when only one b-
thalassaemia allele is 
inherited (Vetter et al. 2000; 
Efremov 2007). 
b-thalassaemia 
major HBB 
b0/b0 
 
b0/b+ 
 
b+/b+ 
a-globin 
normal 
 
b-globin 
greatly 
reduced 
or absent 
Production of Hb A is either 
greatly reduced or totally 
stopped when two b-
thalassaemia alleles are 
inherited. A transfusion 
dependent phenotype 
normally results. 
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2.3.2 Variant Haemoglobins 
Most variant haemoglobins are caused by a single missense mutation in one of 
the globin genes leading to a single amino acid change in the corresponding 
globin chain (Hbvar 2017). More rarely, two missense mutations in the same 
allele may give rise to a variant. For example, the b-globin variant Hb S Oman is 
the result of two mutations, one the first exon and one in the third exon of the 
HBB gene (Nagel et al. 1998). In general, deletions affecting the globin loci give 
rise to thalassaemia rather than haemoglobin variants. However, there are rare 
exceptions, for example Hb Lepore is the consequence of a large deletion 
affecting the b-globin locus resulting in a functional db fusion gene (Pirastru et al. 
2017). To date 1072 different abnormal haemoglobin variants have been 
described as a result of mutations occurring in the HBA, HBA2 or HBB genes 
(Hbvar 2017).  
Variant haemoglobins differ greatly in clinical significance. Most variants are 
benign in the heterozygous form and some have little, or no, clinical significance 
even in the homozygous form, for example Hb Fontainebleau (see section 7). 
However, others can result in severe and even life-threatening disease for 
example Hb E (see section 2.3.2.1) and Hb S (see section 2.3.2.2). Thus, it is 
important to identify any variant detected in order to assess its clinical relevance. 
A number of pathological mechanisms may result in a variant haemoglobin 
assuming clinical significance (Thom et al. 2013), these include reduced stability, 
changes to oxygen affinity (Figure 3), reduction in globin synthesis rate, changes 
to iron oxidation state and a tendency to polymerase or crystalize (Table 7).  
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Table 7: The pathological mechanisms of variant haemoglobins 
 
  
Pathological 
mechanism Examples Clinical significance 
Increased oxygen 
affinity 
Hb Abrazzo 
(Shirkhande & Pawar 2016) 
 
Hb Bakersfield 
(Brunner-Agten et al. 2017) 
In high oxygen affinity variants, the R 
(oxygenated) state of the haemoglobin 
molecule is stabilized and thus oxygen 
release to the tissues is impaired. This 
results in compensatory erythrocytosis. 
High oxygen affinity variants are caused 
by mutations affecting the a1b2 interface 
that favour the R state or by mutations 
that inhibit 2,3DPG binding. 
Decreased 
oxygen affinity 
Hb Vigo 
(Ma Pereira et al. 2017) 
 
Hb Prebyterian 
(Pernudy-Ubau et al. 2017) 
In low oxygen affinity variants, the T 
(deoxygenated) state of the haemoglobin 
molecule is stabilized and thus oxygen 
uptake in the pulmonary circulation is 
impaired. This results in cyanosis and 
anaemia. Low oxygen affinity variants are 
caused by mutations of the a1b2 interface 
that favour the T state. 
Unstable 
haemoglobin 
Hb Köln 
(Li et al. 2016) 
 
Hb Alesha 
(Jiang et al. 2016) 
Mutations affecting the a1b2 interface, the 
haem pocket or the formation of the globin 
a-helix can result in the formation of 
unstable haemoglobin variants. Also, 
mutations that remove the stop codon can 
result in abnormally long globin chains 
which are unstable. Depending on the 
mutation these haemoglobins vary from 
mildly unstable to hyper-unstable. The 
clinical significance depends on the 
degree of instability. Hyper-unstable 
variants result in a form of autosomal 
dominant thalassaemia. 
Reduced globin 
synthesis rates 
Hb E 
(Sae-ung et al. 2012) 
 
Hb North Shore 
(Smith et al. 1983) 
Variants that are synthesised at 
significantly reduced rates can cause or 
contribute to thalassaemia syndromes.  
Hb E / b-thalassaemia has a thalassaemia 
major or NTDT phenotype and is one of 
the most common severe 
haemoglobinopathies in Southeast Asia. 
Met 
haemoglobins 
 
(Fe oxidation) 
Hb M Iwate 
(Vianaa & Belisáriob 2014) 
 
Hb M Saskatoon 
(Thom et al. 2013) 
Mutations associated with the haem 
pocket may promote auto oxidation of 
haem iron from Fe2+ to Fe3+. Carriers may 
have significant pseudo cyanosis, but are 
usually asymptomatic. 
Haemoglobin 
polymerisation or 
crystallisation 
Hb S 
(Howard & Robinson 2016) 
 
Hb C 
(Cook et al. 2012) 
Some haemoglobin variants have a 
tendency to either polymerise or 
crystallise. This leads to haemolysis and 
in the case of Hb S to a severe syndrome 
resulting in significant morbidity and 
mortality. 
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Globally the two most clinically significant variant haemoglobins are Hb E 
(HBB:c.79G>A) and Hb S (HBB:c.20A>T). These two variants are of particular 
importance because they are both very common and can both result in very 
severe phenotypes. These two variants are described in more detail below. 
 
2.3.2.1 Haemoglobin E 
The Hb E is common throughout Southeast Asia reaching frequencies of 50% in 
North-eastern Thailand (Sae-ung et al. 2012) and up to 60% along the Laos / 
Cambodia border (Fucharoen & Winichagoon 2011). Hb E is a stable and 
functional variant; heterozygous carriers are asymptomatic and homozygotes 
typically exhibit only mild microcytosis. It is therefore paradoxical that Hb E is 
associated with one of the most commonly occurring severe 
haemoglobinopathies. When the Hb E is inherited in combination with b-
thalassaemia a NTDT, or even thalassaemia major, phenotype results. This 
unexpected behaviour from an otherwise benign variant is due to the fact that the 
Hb E mutation introduces a cryptic splice site in the first exon of the HBB gene 
(Olivieri et al. 2011; Tubsuwan et al. 2011).  As shown in Figure 10, this cryptic 
splice site exerts a thalassaemic effect by reducing the amount of viable mRNA 
produced. When the other HBB allele is compromised this can be sufficient to 
result in severe disease.  
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Figure 10: The molecular basis of Hb E / b-thalassaemia disease. The mutation responsible 
for the variant haemoglobin Hb E (HBB:c.79G>A) introduces a cryptic splice site in the first exon 
of the HBB gene. When the pre-mRNA is spliced it may be spliced correctly to produce a transcript 
that is translated to form the bE-globin, which combines with a-globin to form Hb E. Alternatively 
the pre-mRNA may be aberrantly spliced using the cryptic site. Aberrant splicing results in mRNA 
transcript with missing bases, a frame shift error and a premature stop codon. The aberrant mRNA 
cannot be translated into a viable b-globin chain. Consequently, the cryptic splice site has a 
thalassaemic effect due the reduction in viable mRNA. If the other HBB allele is non-functional 
due to a b0 mutation the loss of mRNA caused by the cryptic slice site is sufficient to result in a 
severe thalassaemia phenotype (Olivieri et al. 2011; Tubsuwan et al. 2011). 
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2.3.2.2 Haemoglobin S 
Hb S is a common variant haemoglobin encountered in people of African or Asian 
ancestry (Howard & Robinson 2016).  Hb S results from single point mutation in 
the HBB gene (HBB:c.20A>T) (Habara & Steinberg 2016). The various 
syndromes caused by Hb S, collectively referred to as sickle cell disease (SCD), 
are described in Table 8. The pathology of SCD is due to Hb S being more 
hydrophobic than Hb A and consequently having tendency to polymerise leading 
to the formation of sickle cells (Galkin et al. 2007) (Figure 11).  
SCD is recognized by the United Nations General Assembly as “one of the most 
lethal genetic diseases” (United Nations 2009). In sub-Saharan African 3% of 
children are born with this condition, access to modern health care is generally 
poor resulting in childhood mortality rates ranging from 50% to 90% (Grosse et 
al. 2011; Noubouossie et al. 2016). In the North America and Europe, where 
survival rates are much higher (Aygun & Odame 2012), the health related quality 
of life remains poor (Panepinto & Bonner 2012; Senol et al. 2016).  
SCD is a multi-organ disease with common complications including cardiac 
abnormalities (Gladwin & Sachdev 2012), pulmonary problems (Khoury et al. 
2011; Gordeuk et al. 2016), strokes (Jordan et al. 2012; Jone et al. 2016; 
Lawrence & Webb 2016), impaired renal function (Silva Junior et al. 2012), 
compromised cognition (Wang 2011), increased risk of infection (Ngwube et al. 
2012), osteonecrosis (Gatin et al. 2016) and severe leg ulcers that can result in 
the need for amputation (Ladizinski et al. 2012; Maximo et al. 2016). 
	 46	
Table 8: Different syndromes resulting in sickle cell disease 
Disease Genotype Clinical significance 
Sickle cell anaemia βSβS 
The term sickle cell anaemia refers to the form of sickle 
cell disease resulting from homozygosity for the bS 
allele. This leads to a severe phenotype with recurrent 
painful crises and complications including cardiac and 
pulmonary problems, strokes and leg ulcers. A milder 
phenotype is associated with elevated levels of HB F or 
co-inheritance of a-thalassaemia (Rees et al. 2010; 
Thein 2011; Habara & Steinberg 2016). 
Hb S / b-thalassaemia 
βSβo 
 
or 
 
βSβ+ 
The phenotype is usually similar to sickle cell anaemia, 
but may be milder, depending of the severity of the  
β-thalassemia allele (Habara & Steinberg 2016). 
Sickle C disease βSβC 
Compound heterozygosity for Hb S and Hb C results in 
a form of sickle cell disease. The phenotype is variable, 
but generally similar to that of sickle cell anaemia 
(Hannemann et al. 2011; Oteng-Ntim et al. 2014; 
Benites et al. 2016; Rosenberg et al. 2016). 
Sickle D disease βSβD 
Compound heterozygosity for Hb S and Hb D results in 
variable phenotypes, ranging from severe to 
asymptomatic (Patel et al. 2014; Ahmad et al. 2014; 
Afzal & Umair 2016; Torres et al. 2016). 
Sickle E disease βSβE 
Co-inheritance of Hb S and Hb E can cause a mild form 
of sickle cell disease and up to 60% of patients may be 
asymptomatic (Mishra et al. 2005; Tay et al. 2012; 
Baciu et al. 2014; Acipayam et al. 2015). 
Autosomal dominant 
sickle cell disease 
βS Omanβ 
 
and 
 
aa/aa 
Rare Hb S variants such as Hb S Oman can result in a 
dominantly inherited form of sickle cell disease. Co-
inheritance of a-thalassaemia is significant ameliorating 
factor in such cases (Nagel et al. 1998). 
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Figure 11: The pathology of sickle cell disease – see following page for legend 
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Legend for figure 11 (previous page): (1) Normal red cells are flexible and move easily through 
fine capillaries. Nitrous oxide (NO) maintains the tone of the blood vessels and any haemoglobin 
that is released is rapidly bound to haptoglobin and removed from the circulation (Kato & Gladwin 
2009). (2) Polymerisation of Hb S in old or dehydrated cells results in the formation of sickle cells, 
leading to occlusion of fine capillaries. (3) Complement mediated lysis of sickle cells removed the 
blockages, but releases free haemoglobin into the circulation (Kato & Gladwin 2009). (4) Free 
haemoglobin removes NO which has a negative impact on the vascular integrity (Rees et al. 
2010; Habara & Steinberg 2016). Also, free radicals released by cells dying in inadequately 
perfused tissues cause reperfusion injury. The resulting damage to the vascular tissue increases 
the probability of sickle cells becoming trapped and so sets up a cycle which ultimately leads to 
chronic tissue damage and necrosis due in inadequate oxygenation (Rees et al. 2010; Habara & 
Steinberg 2016).  
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 2.4 Prevention of inherited haemoglobin disorders 
Premarital screening programs have proved to be a very successful strategy for 
preventing inherited disorders of haemoglobin. In Cyprus during the 1970’s an 
average of 20 children were born each year with b-thalassaemia major, placing 
a considerable strain on the resources of health care system. In 1979 a premarital 
screening program was introduced (Cowan 2009) and by the 1990’s less than 
one child with b-thalassaemia major was being born per year (Bozkurt 2007).  
Following the success of pre-marital screening in Cyprus, programs have also 
been introduced in a number of other countries. In Iran screening resulted in a 
70% reduction of b-thalassaemia major births (Haddow 2005; Strauss 2009). 
Successful programs have also been reported in Thailand (Yamsri et al. 2010), 
Turkey (Arica et al. 2012; Canatan & Delibas 2016), the Gaza Strip (Tarazi et al. 
2007) and Jordan (Alkhaldi et al. 2016).  
In addition to the obvious social benefits of reducing the number of severely sick 
children, screening for haemoglobinopathies also has a significant economic 
impact. In the UK it has been estimated that screening programs prevent 476 
cases of severe haemoglobinopathies per year (Bain 2011). The average medical 
costs for supporting a thalassaemia major patient in the UK are currently 
estimated to be £9,669 per year (Weidlich et al. 2016). Thus, if the life expectancy 
of an individual with a severe haemoglobinopathy is assumed to be 50 years, UK 
screening programs have the potential to save the National Health Service in 
excess of £200,000,000 per year. In the United States the annual cost of treating 
severe haemoglobinopathies have been estimated to range from £37,225 to 
£47,125, (Vekeman et al. 2016). Haemoglobinopathies are most prevalent in 
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lower income countries, where this kind of expenditure is not possible and as a 
result many patients receive sub-optimal care (Noubouossie et al. 2016). 
It is important to note that not all screening programs have been equally 
successful. In China voluntary pre-marital screening programs were hampered 
by poor participation (Li 2009; Sleeboom-Faulkner 2011). While in India the 
stigma of “rakter dosh” – corrupt blood, has been blamed for the limited initial 
enthusiasm for screening (Chattopadhyay 2006), although successful programs 
were subsequently implemented (Bhattacharyya et al. 2016).  
Evaluation of both the successful and less successful screening programs has 
led to the identification of three key elements that are required to maximize 
effectiveness. Firstly, the population being screened must be educated about the 
disease, so that they understand the benefits of participation in the program. 
Secondly genetic counselling must be available so that carriers can have the risks 
and their options explained to them. Thirdly accurate detection of carriers is 
required (Giordano 2009).   
The WHO guidelines state that a reliable diagnostic test is a prerequisite for any 
screening program (Wilson & Junger 1968) and others have noted that in 
haemoglobinopathy screening each carrier that is missed has the potential to 
discredit the entire program (Cao 2002; Gibson et al. 2012). Consequently, the 
success of screening programs is closing linked to the performance of the 
laboratory tests used to diagnose haemoglobinopathy carriers. Indeed, in 
retrospective study of b-thalassaemia major births in Taiwan revealed that failure 
to correctly identify carriers accounted for 68 of 97 cases making it the single 
biggest factor limiting the success of the program (Chern et al. 2008). 
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2.5 Laboratory testing for haemoglobinopathies 
Various tests are used in the clinical laboratory for the detection and identification 
of haemoglobinopathies. These can be conveniently divided into two broad 
categories, the conventional biochemical or non-molecular tests (Section 2.5.1) 
and molecular tests (Section 2.5.2).  
 
2.5.1 Non-molecular techniques 
The non-molecular techniques used to assist in the laboratory diagnosis of a 
haemoglobinopathy are summarized in Table 9.  
The most important technique is haemoglobin analysis, which allows the 
detection of variant haemoglobins and the simultaneous quantification of Hb A2. 
Haemoglobin analysis is usually performed by either cation exchange high 
performance liquid chromatography (HPLC) (Szuberski et al. 2012) or capillary 
electrophoresis (CE) (Cotton et al. 1999). The relative merits of these two 
techniques have been extensively reviewed and compared (Keren et al. 2008; 
Higgins et al. 2017; Borbely et al. 2013; Stephens et al. 2015). Also, although 
less widely used mass spectrometry can detect variant haemoglobins (Wild et al. 
2004; Daniel et al. 2005; Kleinert et al. 2008; Das et al. 2016), however attempts 
to utilise this technology to detect thalassaemia have so far been unsuccessful 
(Helmich et al. 2016). 
The diagnostic difficulty with variant haemoglobins is not normally detection of 
the abnormal haemoglobin, but correctly determining the identity of the 
haemoglobin variant once detected. This can be challenging since more than a 
thousand haemoglobin variants have been described (Hbvar 2017) and for many 
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of these the characteristics such as peak position and shape on HPLC and CE 
are not well documented. 
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Table 9: Non-molecular tests for the diagnosis of haemoglobinopathies 
Type of 
investigation Test Description 
Routine 
clinical 
laboratory 
investigations 
Full blood count 
Severe haemoglobinopathies often have profound 
anaemia. Microcytosis in association with a raised 
red cell count is suggestive of thalassaemia trait. 
Peripheral blood film 
Sickle cells are usually seen in cases of sickle cell 
disease. Hb C crystals may be seen in cases of Hb C 
disease. Target cells are often seen in cases of 
variant haemoglobins. Thalassaemia trait normally 
shows target cells and microcytosis. 
Serum iron or Ferritin 
Both thalassaemia trait and iron deficiency cause 
microcytosis. Assessment of the patient’s iron status 
is therefore useful.  
Tube tests for 
solubility / 
haemolysis 
Naked eye single 
tube osmotic fragility 
(NESTOF) 
NESTOF is fast and cheap way to screen for 
thalassaemia. However, it has poor sensitivity and 
specificity and is not generally used in environments 
where more sophisticated tests are available.  
Sickle cell solubility 
test 
Solubility in sodium meta-bisulphate solution is a 
quick and reasonably reliable test for sickling 
haemoglobins. 
Dichlorophenol indo-
phenol test (DCIP) 
A cheap simple test for Hb E, but has significant false 
positive rate. 
Haemoglobin 
analysis 
Cation exchange 
high performance 
liquid 
chromatography 
(HPLC) 
HPLC can detect most Hb variants and also allows 
accurate quantification of Hb A2 and Hb F. HPLC is 
not sensitive enough to detect Hb H in  
a-thalassaemia trait, but can usually identify Hb H 
disease. 
Globin chain HPLC 
Specialize technique to identify Hb variants. Now 
rarely used, since sequencing has become more 
readily available.  
Capillary 
electrophoresis (CE) 
CE is an alternative to HPLC for haemoglobin 
analysis and generates very similar data. 
Acid and alkaline gel 
electrophoresis 
Gel electrophoresis at acid or alkaline pH can help 
identify variants detected by HPLC or CE. 
Isoelectric focusing Now largely replaced by HPLC and CE, which give similar information, but are easier to perform. 
Mass spectroscopy 
Not widely used, but has the potential to be useful in 
neonatal screening for Hb S since it is faster than 
HPLC or CE. 
 Supravital 
staining 
New methylene blue 
staining for Hb H 
Used to detect a-thalassaemia trait and Hb H 
disease. Cannot detect a+-thalassaemia alleles. 
Colourmetric 
assays 
Immunoassay for Hb 
Bart’s 
An assay using a monoclonal antibody targeting Hb 
Bart’s. Able to detect a0 but not a+ alleles. 
Immunoassay for 
Hb S 
A point of care strip assay for detection of Hb S. Able 
to detect both SCD and sickle cell trait. 
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For variant haemoglobins that are well documented the behaviour of the variant 
when analysed by various techniques including HPLC, CE and gel 
electrophoresis at varying pH may provide sufficient information to allow 
presumptive identification. For poorly documented variants sequencing of the 
globin genes is now the preferred approach (Greene et al. 2015) and has largely 
replaced alternative biochemical techniques such as isoelectric focusing 
(Campbell et al. 1999), globin chain analysis (Wajcman et al. 2002; Wajcman & 
Riou 2009) and peptide fingerprinting (Marengo-Rowe et al. 1968).  
Haemoglobin analysis by HPLC or CE allows accurate quantification of Hb A2, 
which is mildly elevated in most b-thalassaemia carriers, making it a useful 
marker for the disease (Ryan et al. 2010). However, Hb A2 levels are affected by 
several factors (Table 10). The incidence of patients with borderline Hb A2 results 
that cannot be reliably interpreted range from 2.2% to 16.7% depending on the 
population being studied (Lou et al. 2014). Consequently, although Hb A2 
quantification is a useful tool when screening for b-thalassaemia, confirmation by 
molecular analysis is frequently required (Ivaldi et al. 2014; Wajcman et al. 2017).  
Haemoglobin analysis is not useful for the detection of a-thalassaemia trait since 
Hb H levels are below the lower limit of detection (Turley et al. 2015; Wu et al. 
2015). Various biochemical techniques have been developed for the diagnosis of 
a-thalassaemia by the detection for Hb H or Hb Bart’s including isoelectric 
focusing, supravital staining and immunochromgenic assays, however none of 
these methods are able to robustly detect a+-thalassaemia (Thompson et al. 
1989; Kulac et al. 2009; Agarwal et al. 2013; Winichagoon et al. 2015). 
Consequently, reliable detection of a-thalassemia trait by non-molecular 
techniques is not possible.  
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Table 10: Factors affecting Hb A2 levels 
Factor Examples and references Effect on Hb A2 levels 
Mutations the 
globin genes 
b-Thalassaemia trait 
(Ryan et al. 2010; Stephens 
et al. 2011) 
b-Thalassaemia trait resulting from b0 or b+ 
mutations is normally associated with an 
elevated Hb A2 level.  
 
However, with b++ alleles a measurable 
increase in Hb A2 is not always present. 
Large deletions of the  
b-globin locus 
(Panyasai et al. 2004) 
Deletions affecting the HBB gene will 
generally result in elevated Hb A2 levels.  
However, if the deletion also affects the 
HBD the Hb A2 level will remain normal. 
d-Thalassaemia and d-globin 
chain variants 
(Jain et al. 2012; Colaco et 
al. 2014; Hassan et al. 2014; 
Yan et al. 2015; Hariharan et 
al. 2016; Villegas et al. 2017) 
d-thalassaemia resulting from deletions or 
point mutations of the HBD gene will lower 
Hb A2 levels. This can result in Hb A2 
levels that are normal or low even when a 
b-thalassaemia allele is co-inherited. 
 
d-variants normally result split the Hb A2 
peak, complicating quantification. 
g-Thalassaemia 
(Parmeggiani et al. 2016) 
Some cases of g-thalassaemia may be 
associated with elevated levels of Hb A2 
even though the HBB gene is unaffected. 
Such cases are rare and the mechanism is 
uncertain.  
a-Thalassaemia and a-globin 
gene duplications 
(Harteveld & Higgs 2010; 
Wajcman et al. 2017) 
Hb A2 levels are lowered in a-thalassaemia 
and elevated in cases with an excess of a-
globin genes. 
Variant haemoglobins 
(Stephens et al. 2011; 
Greene et al. 2015) 
b-Globin variants usually result in elevated 
Hb A2. 
 
a-Globin variants generally lower the Hb 
A2 level and may also complicate 
quantification by splitting the peak. 
 
Hb E elutes with Hb A2 by HPLC and Hb C 
migrates  with Hb A2 by CE. Also, Hb S 
may falsely elevate Hb A2 measurement by 
HPLC since HbS1c elutes with Hb A2. 
Mutations 
outside of the 
globin loci 
Mutations of the KLF1 gene 
(Perseu et al. 2011) 
Various mutations of the KLF1 gene have 
been associated with elevated Hb A2. 
Disease and 
medication 
Iron deficiency 
(Galanello et al. 1981; 
Sharma et al. 2015) 
Iron deficiency lowers Hb A2 levels.  
Hyperthyroidism 
(Kendall & Bastansky 1981) 
Hb A2 levels are elevated in 
hyperthyroidism. 
Human immunodeficiency 
virus (HIV) infection 
(Routy et al. 1993; 
Pornprasert et al. 2009) 
Zidovudine (AZT) treatment has been 
shown to elevate Hb A2 levels. 
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2.5.2  Molecular techniques 
The various molecular techniques used for the investigation of 
haemoglobinopathies are summarized in Table 11. 
 
2.5.2.1 Gap-PCR 
Most a-thalassaemia alleles and some b-thalassaemia alleles are the result of 
gene deletions (Harteveld & Higgs 2010). Thus, the ability to detect deletions of 
the globin genes is essential for the molecular diagnosis of thalassaemia. In the 
clinical laboratory setting Gap-PCR assays are widely used for this purpose. Gap 
is not an abbreviation or mnemonic, but rather the name of the technique. The 
principle of Gap-PCR is illustrated in Figure 12.  
Various multiplex Gap-PCR assays have been described targeting the most 
common a-globin gene deletions (Chong et al. 2000; Liu et al. 2000; Tan et al. 
2001; de Mare et al. 2010). Gap-PCR assays have also been developed for two 
of the more common b-globin gene deletions (Yamashiro et al. 2012; Saetung et 
al. 2013). However, Gap-PCR is not an ideal technique for high throughput 
testing since use of agarose gel electrophoresis to determine the size of the PCR 
products is time consuming and labour intensive. Another important limitation of 
Gap-PCR is that it can only be used to detect specifically targeted deletions with 
previously defined breakpoints. Consequently, Gap-PCR is not well suited for the 
detection of rare or novel deletions.  
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Table 11: Molecular tests for the diagnosis of haemoglobinopathies 
Application Technique Advantages Limitations 
Detection of 
specific large 
gene deletions 
with known 
breakpoints 
Gap-PCR 
Cheap, simple and 
robust. Presumptive 
identification of any 
deletions detected. 
Can only detect deletions with 
known beak points. Time 
consuming due to long PCR 
extension times and the use of 
agarose gel electrophoresis for 
detection. Approximately one day 
required to run a batch of 
specimens. Not readily automated 
or well suited for high volume 
testing. The use of ultra violet light 
and ethidium bromide for detection 
is potentially harmful. 
Melting curve 
methods 
Closed tube, high 
throughput methods 
with simple analysis. 
Readily automated 
and well suited to high 
volume testing with 
batches taking 
approximately two 
hours to process. 
Can only detect a limited number 
of specifically targeted deletions 
and duplications. 
Reverse 
hybridization 
Positive identification 
of any deletions 
detected. Limited 
automation of the 
hybridization and 
washing steps is 
possible. 
Time consuming due to 
hybridization and washing steps, 
typically taking one day to process 
a batch. Can only detect 
specifically targeted deletions and 
duplications. 
Denaturing high 
performance 
liquid 
chromatography 
(DHPLC) 
Potentially high 
throughput with 
automation of the 
chromatography step.  
Specialised equipment required. 
Assays described for a limited 
number of deletions. Time required 
to process a batch largely depends 
on the number of samples, with 
the detection step typically taking 
around 10 minutes per sample. 
Detection of 
known and 
unknown large 
gene 
rearrangements 
Multiplex 
ligation-
dependent 
probe 
amplification 
(MLPA) 
Can detect known and 
novel gene deletions 
or duplications. 
Approximate break-
points are determined. 
Too time consuming and 
expensive to be used for routine 
diagnostics. Ligation step is often 
run overnight, so it can take two 
days to process a batch. Detection 
requires the use of a genetic 
analyser. 
Fragment 
analysis by 
capillary 
electrophoresis 
Published methods for 
the detection of a-
globin gene deletions. 
Detection step can be 
automated. 
Interference from the African a2 
polymorphism. Time consuming, 
taking around one day to process 
a batch. A genetic analyser is 
required for detection. 
Quantitative 
PCR (qPCR) 
Rapid closed tube 
technique that can be 
readily automated. 
Each batch takes 
approximately two 
hours to process. Able 
to detect novel 
deletions.  
Requires the use of multiple PCR 
reactions or probes. Does not 
identify any deletions detected. 
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Table 11 continued 
Application Technique Advantages Limitations 
Detection of 
specific point 
mutations / 
indels 
Amplification 
refractory 
mutation system 
(ARMS) PCR 
Cheap and simple. 
Time consuming taking around 
one day to process a batch. Open 
tube technique using agarose gel 
electrophoresis for detection. The 
use of ultra violet light and 
ethidium bromide is potentially 
harmful. Only detects specific 
targeted mutations.  
Allele specific 
oligonucleotide 
(ASO) PCR / 
reverse 
hybridization 
Cheap and simple. 
Hybridization step can 
be partially automated. 
Time consuming taking around 
one day to process a batch. Open 
tube technique. Only detects 
specific targeted mutations. 
Real-time PCR 
Rapid, closed tube 
technique. High 
throughput and readily 
automated. Each 
batch takes 
approximately two 
hours to process.  
Only able to detect specific 
targeted mutations. Requires the 
use of expensive probes / 
quenchers. 
Gene scanning 
for the 
detection of 
point mutations 
/ indels 
Denaturing 
gradient gel 
electrophoresis 
(DGGE) 
Gene scanning is 
significantly cheaper 
than gene sequencing. 
Open tube method that is not 
readily automated. Electrophoresis 
step takes several hours and is 
often performed overnight. 
Potential chemical hazard due to 
use of acrylamide which is a 
potential carcinogen. 
Single strand 
conformational 
polymorphism 
(SSCP) 
Gene scanning is 
significantly cheaper 
than gene sequencing. 
Open tube method that is not 
readily automated. Electrophoresis 
step takes several hours and is 
often performed overnight. 
Potential chemical hazard due to 
use of acrylamide which is a 
potential carcinogen. 
High resolution 
melting (HRM) 
PCR 
Cheap, high 
throughput, closed 
tube. With appropriate 
automation, a batch 
can be completed in 
around two hours with 
no further hands on 
time required after the 
initial PCR setup.  
Requires relatively short amplicons 
compared to other gene scanning 
technologies. Consequently, more 
PCR reactions are required to 
scan a given gene. SNP 
interference can be problematic. 
Definitive 
identification of 
point mutations 
/ indels 
Sanger 
sequencing 
Reference method for 
detection and 
identification of point 
mutations / indels. 
Some automation is 
possible. 
Expensive, time consuming 
typically taking around two days to 
process a batch. Limited ability to 
detect large gene rearrangements. 
Next Generation 
Sequencing 
(NGS) 
Very high throughput 
compared to Sanger 
sequencing. Various 
options for automation. 
Short read lengths complicate the 
detection of gene duplications and 
deletions. Library preparation is 
complex and may take one or 
more days. Relatively expensive. 
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Figure 12: Gap-PCR for the detection of deletions. Gap-PCR is a useful and simple technique 
for the detection of deletions and insertions. In the above diagram two alleles are shown, the 
allele with the deletion contains a shorter red section. If PCR is performed on genomic DNA with 
primers targeting sequences on either side of the breakpoint then the wild type allele will result in 
a long PCR product and the allele containing the deletion will result in a shorter PCR product. 
The length of the PCR products is estimated by agarose gel electrophoresis, thus allowing 
detection of the deletion. 
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2.5.2.2 Gene scanning techniques 
Traditional PCR techniques such as Amplification Refractory Mutation System 
(ARMS) PCR, Allele Specific Oligonucleotide (ASO) PCR and real time PCR 
have all been successfully employed to detect haemoglobinopathies resulting 
from point mutations or indels (Old et al. 2000; Old 2003; Vrettou et al. 2003). 
However, these assays are designed to test for a small number of predetermined 
mutations, which limits their efficacy when testing in highly heterogeneous 
populations.  
The large numbers of mutations associated with the haemoglobinopathies makes 
gene scanning an attractive alternative approach. Methods using various gene 
scanning technologies including Denaturing High Performance Liquid 
Chromatography (DHPLC), Single Strand Conformational Polymorphism (SSCP) 
and Denaturing Gradient Gel Electrophoresis (DGGE) have been described for 
the HBB (Patrinos et al. 2005). 
An alternative technology called High Resolution Melting PCR (HRM-PCR) offers 
potential advantages over the other gene scanning techniques in that it does not 
require complicated post amplification processing by chromatography or 
polyacrylamide gel electrophoresis (Erali & Wittwer 2010).  
HRM-PCR is an enhanced version of conventional PCR melt curve analysis, 
made possible by the development of specialized dyes that can be used at 
saturating concentrations without inhibiting PCR (Figure 13) (Radvanszky et al. 
2015) and by the availability of thermal cyclers with very precise temperature 
control (Erali & Wittwer 2010).  
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Figure 13: Dye jumping. Conventional DNA intercalating dyes such as SYBR Green 1 cannot 
be used at saturating concentration, since they will inhibit PCR. Consequently, there are vacant 
binding sites in the DNA helix. As melting starts, released dye molecules can relocated to the 
vacant positions, a phenomenon known as dye jumping (top). In contrast, the new generation of 
HRM dyes can be used at saturating concentrations, thus dye jumping is eliminated and the 
observed drop in fluorescence more accurately reflects the degree of amplicon melting (bottom). 
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HRM-PCR works on the principle that the presence of a mutation in an amplicon 
will result in subtle but reproducible changes in the melting behaviour (Erali & 
Wittwer 2010). These changes are detected by melting the amplicon in a very 
carefully controlled manner and measuring the fall in fluorescence as an 
intercalating dye is released (Figure 14).  
Analysis of HRM-PCR melt curves allows different genotypes to be distinguished 
by visual examination of the normalized data as shown in Figure 15. Thus, HRM-
PCR is well suited to clinical applications, since it permits a simple efficient 
workflow, requires no additional hands on time after the initial PCR setup and has 
minimal risk of amplicon contamination. 
In addition to being quicker and easier to perform, HRM-PCR has specificity and 
sensitivity equal to, or better than, other gene scanning technologies such as 
DHPLC (Chou et al. 2005; Sadr-Nabavi et al. 2009). These advantages have 
resulted in the application of HRM-PCR in a wide range of clinical settings (Payne 
et al. 2014; Pickering et al. 2014; Chua et al. 2015; Gorniak et al. 2015; Out et al. 
2015; Oliveira et al. 2016; Wang et al. 2016; Zampieri et al. 2016; Siji et al. 2017). 
HRM-PCR assays for scanning the HBB gene mutations have been described, 
targeting the most common mutations found in Chinese (Lin et al. 2014), South 
East Asian (Shih et al. 2009; Saetung et al. 2013; Prajantasen et al. 2015), Iranian 
(Ramezanzadeh et al. 2016) and Greek (Chassanidis et al. 2016) populations. 
These assays are well suited for screening the specific cohorts targeted. 
However, the approaches used to overcome interference from high frequency 
SNPs made these assays insensitive to some important pathological mutations 
that are common in other populations.  
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Figure 14: The use of HRM-PCR for mutation detection. PCR is used to generate a short 
amplicon. If no mutations are present a single PCR product is formed. However, if a mutation is 
present a mixture of homodimers and heterodimers is formed. Heterodimers are less 
thermodynamically stable and melt at a lower temperature. The use of an intercalating dye that 
is released as the amplicons melt allows these differences in melting behaviour to be detected as 
changes in melting curve shape.  
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Figure 15: HRM PCR data analysis. Raw melt curves are difficult to interpret (A). Normalization 
ranges are set before and after the active melting zone as indicated by the grey bars. Once 
normalized the different genotypes are readily distinguished (B). Sometimes the data is easier to 
interpret when shown as a difference plot (C). 
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3.0 Aims and objectives 
The aim of the current study was the development of HRM-PCR assays suitable 
for the diagnosis of haemoglobinopathies in highly heterogeneous populations 
such as that of the UAE.  
 
Specific objectives were: 
• The development of a closed single tube melting curve assay to detect 
deletions of the HBA1 or HBA2 gene by copy number determination. 
• The development of an enhanced HRM-PCR assay for the detection of 
point mutations and small indels of the HBB gene without interference from 
common SNPs. 
• The development of closed tube melting curve based methods for the 
detection of both known and unknown deletions of the HBB gene. 
• To gain further insight into the molecular basis of haemoglobinopathies in 
the population of the UAE. 
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4.0 Methods 
4.1  DNA Extraction 
Genomic DNA was extracted from whole blood using the QIAamp DNA Blood 
Mini kit (Qiagen, Germany) in accordance with the Manufacturer’s instructions. 
The concentration of the extracted DNA was measured using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, USA) and adjusted to 10 ng/µl with 10 mM 
Tris, 0.5 mM EDTA (pH 9.0). 
 
4.2 Primer design and synthesis 
Primers were designed using Oligo Primer Analysis Software version 7.56 
(Molecular Insights, USA). All primers were checked for specificity using the 
National Centre of Biotechnology Information (NCBI) Primer BLAST program 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). HPLC purified primers and 
probes were commercially synthesized (Metabion, Germany). 
 
4.2.1 Primer design for the a-globin Gene Ratio Assay Copy Enumeration 
(GRACE) PCR assay 
To detect deletions in HBA1 and HBA2 genes simultaneously three primer pairs 
targeting the HBA1, HBA2 and chloride channel voltage sensitive 7 (CLCN7) 
genes were used in the GRACE-PCR assay (Table 12). The approximate location 
of the amplification sites for the HBA1 and HBA2 genes along with the locations 
of the deletions identified in the current study are shown in Figure 16. Primers 
were specifically designed to work at the same annealing temperatures, but to 
generate products with melting temperatures approximately 3 °C apart.  
	 67	
An optional alternative primer set was also developed to amplify HBA2 and 
CLCN7 genes that could be used to investigate any anomalous results from the 
original GRACE-PCR (Table 12). 
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Table 12: Primers for the GRACE-PCR alpha globin copy number assay.  
Primer Set Primer Direction Primer Sequence 5'-3' 
Target 
Gene 
symbol 
Product 
size (bp) 
Product 
Tm (oC) 
Position on Ref 
Sequence 
NC_000016.10 
GRACE-
PCR 
primers 
Forward CACCCGGCCTCATGGAT 
CLCN7 155 79.4 1,462,101 to 1,462,255 Reverse AAGAGAACTACAGACCAACACCC 
Forward CCATCTTTACGTTTCTGGGCACTC 
HBA1 131 82.2 177,800 to 177,930 Reverse GCCATGCTGGAGTGGGACTTC 
Forward CCGTTAAGCTGGAGCCTCGGT*A 
HBA2 171 85.2 173,594 to 173,764 Reverse ACACCTCCATTGTTGGCACAT 
GRACE-
PCR 
alternative 
primers 
Forward ATCAGCCTGTTTCCATAGAACC 
CLCN7 194 
 
83.2 1,473,158 to  1,473,351 Reverse GCCCCATCACTTCAAATTAACCC 
Forward GCCGTTCCTCCTGCCCGCTG 
HBA2 173 
 
86.6 173,616 to 173,788 Reverse AGGTCCTTGGTCTGAGACAGGT 
 
*indicates the use of phosphorothioate (PTO) to block 3’ exonuclease activity. 
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Figure 16: A schematic representation of the a-globin locus from the Haemoglobin subunit 
zeta (HBZ) gene to the non-functional Haemoglobin subunit theta 1 (HBQ1) gene. The 
approximate position of the gene deletions detected in the current study is shown. The location 
of amplicons targeting the HBA1 and HBA2 genes are indicated by the arrows A1 and A2, 
respectively. The CLCN7 gene is located approximately 1.3 million bases 3’ of the a-globin locus 
(not shown). Figure from Turner et al. 2015 BMC Medical Genetics, 16:115 (Creative Commons 
Licence http://creativecommons.org/licenses/by/4.0/). 
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4.2.2 Primer and probe design for the HBB gene HRM / GRACE-PCR assay 
Analysis of the HbVar online database (http://www.globin.bx.psu.edu/hbvar/) was 
performed to identify the regions of the HBB gene of potential clinical relevance 
and to identify the breakpoints for known gene deletions. The final version of the 
assay used a total of 13 PCR reactions, 11 HRM-PCRs to scan for point 
mutations and indels of the HBB gene and two GRACE-PCRs for the detection 
of larger gene rearrangements (Table 13 and Figure 17).  
The previously described primer set H7 (Lin et al. 2014) was included to test for 
the HBB:c.316-197C>T mutation found in intervening sequence two (IVS2). The 
reverse primers in primer sets H6 and H7 incorporated the universal base inosine 
to eliminate interference from common non-pathological SNPs (Table 13). In 
addition, an unlabelled probe was designed to overlap the region of the first exon 
containing the HBB:c.19G>A and HBB:c.20A>T mutations (Table 13 and Figure 
17). This probe was designed to have a melting temperature approximately 8 oC 
lower than the corresponding amplicon and was synthesized with a phosphate 
block at the 3’ prime end to prevent it from acting as a primer.  
Primer sets G1 and G2 were used to amplify targets in the HBB gene promoter 
and third exon, respectively. These primers were designed to be used in GRACE-
PCR with primer set G3, which amplifies a target in the CLCN7 reference gene 
(Fallah et al. 2010) 
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Figure 17: Schematic representation the HBB gene showing amplicon and probe 
positions. A total of 11 primer pairs were used to scan the HBB gene by HRM-PCR (H1 to H11). 
In addition, two primer pairs where used to test for deletions by GRACE-PCR (G1 and G2). An 
unlabelled probe (indicated by P) was used in conjunction with primer set H2. Primer sets H6 and 
H7 incorporated the universal base inosine in place of common non-pathological SNPs (See 
sequence information in Table 13).  
Figure from Turner et al. 2016 BMC Medical Genetics, 17:75 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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Table 13: Primers for HRM-PCR / GRACE-PCR assay of the HBB gene 
Primer 
Set Direction Primer / Probe Sequence (5’ to 3’) 
Position on 
Ref Sequence  
Product 
length 
(bp) 
Target 
Anneal 
Temp 
(oC) 
HRM 
Melting 
Range 
(oC) 
H1 
Forward GGCTGTCATCACTTAGACCTCA 5,227,065 to 
5,227,196 on 
NC_000011.10 
132 HBB Promoter 59 80-90 
Reverse CAAATGTAAGCAATAGATGGCTC 
H2 
Forward ATTTGCTTCTGACACAACTG 
5,226,952 to 
5,227,069 on 
NC_000011.10 
118 HBB Exon 1 55 70-90 Reverse CTTCATCCACGTTCACCTTG 
Probe* CTCCTGAGGAGAAGTCT-GCCGTTACTGCCCTGTGGGG 
H3 
Forward TGCCGTTACTGCCCTGT 5,226,886 to 
5,226,992 on 
NC_000011.10 
107 HBB Exon 1 59 75-85 
Reverse TTCTATTGGTCTCCTTAAACCTGT 
H4 
Forward CACTGACTCTCTCTGCCTA 5,226,726 to 
5,226,841 on 
NC_000011.10 
116 HBB Exon 2 59 80-90 
Reverse TAACAGCATCAGGAGTGGACA 
H5 
Forward GTCTACCCTTGGACCCAG 5,226,674 to 
5,226,789 on 
NC_000011.10 
116 HBB Exon 2 59 80-90 
Reverse CTAAAGGCACCGAGCACT 
H6 
Forward GCTCATGGCAAGAAAGTGCTC 5,226,549 to 
5,226,705 on 
NC_000011.10 
157 HBB Exon 2 59 80-90 
Reverse** GAAAACATCAAGIGTCCCA 
H7 
Forward TGCCTCTTTGCACCATTCTA 5,225,893 to 
5,225,974 0n 
NC_000011.10 
82 HBB IVS2 55 70-80 
Reverse** GAAATATTTATATGCAGAIATATTGCTA 
H8 
Forward CTAATAGCAGCTACAATCCAG 5,225,702 to 
5,225,852 on 
NC_000011.10 
152 HBB IVS2 56 80-90 
Reverse CACAGACCAGCACGTT 
H9 
Forward TTGCTAATCATGTTCATACCTC 5,225,632 to 
5,225,765 on 
NC_000011.10 
134 HBB Exon 3 59 80-90 
Reverse CCAGCCACCACTTTCTGAT 
H10 / 
G2 
Forward GAATTCACCCCACCAGTGC 5,225,559 to 
5,225,678 on 
NC_000011.10 
120 HBB Exon 3 55 80-90 
Reverse AGGAACCTTTAATAGAAATTGGAC 
H11 
Forward CACAAGTATCACTAAGCTCG 5,225,508 to 
5,225,612 on   
NC_000011.10 
105 HBB Exon 3 and 3’ UTR 55 75-85 Reverse TCAAGGCCCTTCATAATATCCC 
G1 
Forward TGAAGTCCAACTCCTAAGCC 5,227,086 to 
5,227,243 on 
NC_000011.10 
158 HBB Promoter 55 75-90 
Reverse TCTGCCCTGACTTTTATGCC 
G3 
Forward CACCCGGCCTCATGGAT 1,462,101 to 
1,462,255 on 
NC_000016.10 
155 
CLCN7 control 
for GRACE 
PCR 
55 NA 
Reverse AAGAGAACTACAGACCAACACCC 
 
Primer sets H1 to H11 were used to scan the HBB gene for mutations by HRM. Primers sets G1 
and G2 were used to detect deletions of the HBB gene promoter and third exon by GRACE-
PCR. Primer set G3 is the internal control for the GRACE-PCR reactions (this primer set is also 
used as the internal control in the a-globin GRACE-PCR assay).  
*Phosphate blocked unlabelled oligonucleotide probe used in conjunction with primer set H2.  
**The reverse primers H6 and H7 contain the universal base inosine, indicated with an I in the 
primer sequence. 
Table from Turner et al. 2016 BMC Medical Genetics, 17:75 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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4.3 PCR methods 
4.3.1 a-Globin gene GRACE-PCR  
Each 12.5 µL GRACE-PCR reaction contained 20 ng of genomic DNA, 0.25 units 
of Kappa HiFi HotStart polymerase (Kappa Biosystems, USA), 0.25 units of 
Platinum Taq polymerase (Invitrogen, USA), 0.5 µL of LightCycler 480 ResoLight 
dye (Roche Diagnostics, Germany), 1x Kappa GC buffer (Kappa Biosystems), 
0.3 mM of each dNTP (Kappa Biosystems), 0.45 µM of each primer for the HBA1 
and HBA2 genes and 0.16 µM of each primer for the CLCN7 gene (Table 12).  
PCR was performed using a Rotor-Gene Q-5plex HRM thermocycler (Qiagen, 
Germany). This system can accommodate up to 72 PCR reactions per run. After 
an initial 5 minute hold at 95 oC, 27 cycles of PCR were performed as follows: 10 
s at 98 oC, 10 s at 58 oC and 10 s at 72 oC. Melting was performed at a rate of 
0.2 oC/s over the temperature range 77 oC to 87 oC, with data acquisition on the 
HRM channel. 
Data analysis was performed using the HRM module Rotor-Gene Q series 
software version 1.7.  
 
4.3.2 a-Globin gene GRACE-PCR using alternative primers 
Each 12.5 μL PCR reaction contained 25 ng of genomic DNA, 0.25 units of 
Platinum Taq polymerase, 0.5 µL of LightCycler 480 ResoLight dye, 1x PCR 
buffer (Invitrogen), 2.0 mM MgCl2, 0.3 mM of each dNTP, 1.2 M betaine (Sigma 
Aldrich, USA) and 0.32 µM of each primer (Table 12). After an initial 5 minute 
hold at 95 oC, 28 cycles of PCR where performed as follows: 5 s at 95 oC, 5 s at 
56 oC, 5 s at 72 oC. Melting was performed from 80 oC to 90 oC at a rate of 0.2 
oC / s, with data acquisition on the HRM channel. 
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Data analysis was performed using the High Resolution Melting (HRM) module 
Rotor-Gene Q series software version 1.7. 
 
4.3.3 HBB gene HRM-PCR / GRACE-PCR 
For scanning the HBB gene by HRM with primers sets H1 to H11 (Table 13) each 
10 µl HRM-PCR reaction included 5 µL of LightCycler 480 High Resolution 
Melting Master (Roche Diagnostics), 3.75 mM MgCl2, 25 ng of genomic DNA and 
0.2 µM of each primer. When an unlabelled probe was included, it was used at a 
concentration of 0.2 µM and the forward primer concentration was reduced to 
0.02 µM. PCR was performed using a Rotor-Gene Q-5plex HRM thermocycler. 
After a 10 minute hold at 95 oC, 45 cycles of PCR were performed as follows: 15 
s at 95 oC, 15 s at the temperature given in Table 13, 15 s at 72 oC. Cycling was 
followed by a 2 minutes hold at 72 oC, a 1 minute hold at 95 oC and then a 1 
minute hold at 40 oC. Amplicon melting was performed at a rate of 0.1 oC / s over 
the temperature ranges indicated in Table 13. Data acquisition and analysis were 
performed using the Rotor-Gene Q series software version 1.7. 
For the detection of deletions in the HBB gene promoter, each 12.5 µL GRACE-
PCR reaction included 0.25 units of Kappa HiFi HotStart polymerase, 0.25 units 
of Platinum Taq polymerase, 1x Kappa GC buffer, 0.3 mM of each dNTP, 0.25 
µL LightCycler 480 ResoLight dye, 25 ng of genomic DNA, 0.16 µM of each G1 
primer and 0.1 µM of each G3 primer (Table 13). After a 2 minute hold at 98 oC, 
26 cycles of PCR were performed as follows: 15 s at 95 oC, 15 s at 55 oC, 15 s 
at 72 oC. Melting was performed from 75 to 90 oC at a rate of 0.2 oC / s.  
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For the detection of deletions in the third exon of the HBB gene, each 10 µL 
GRACE-PCR reaction included 5 µL of LightCycler 480 High Resolution Melting 
Master, 3.0 mM MgCl2, 25 ng of genomic DNA, 0.2 µM of each G2 primer and 
0.08 µM of each G3 primer (Table 13). After an initial 10 minute hold at 95 oC, 26 
cycles of PCR were performed as follows: 15 s at 95 oC, 15 s at 55 oC, 15 s at 72 
oC. Melting was performed from 80 to 90 oC at a rate of 0.2 oC / s 
Data acquisition and analysis were performed using the Rotor-Gene Q series 
software version 1.7 (Qiagen). 
 
4.3.4 Amplicon generation for sequencing the HBA1 and HBA2 genes 
Amplicons for sequencing the HBA1 and HBA2 genes were generated using two 
rounds of PCR. Details of the primers used are given in Table 14. 
Selective amplification of each a-globin gene was achieved using a common 
forward primer HBA_F1, in combination with unique reverse primers HBA_R1 
and HBA_R2 for the HBA1 and HBA2 genes, respectively. The size of the PCR 
products was 1023 bp (reference sequence NT_010393.16 nucleotides 166,596 
to 167,582) for HBA1 and 1008 bp (reference sequence NT_010393.16 
nucleotides 162,792 to 163,763) for HBA2. The amplified products were diluted 
1:100 with nuclease free water and then amplified by a second round of PCR to 
generate shorter products for sequencing. The secondary amplification of the 
HBA1 gene was carried out using primers HBA_F1 with HBA_R3 and HBA_F2 
with HBA_R1 generating 541 bp and 590 bp products respectively. Similarly, 
secondary amplification of the HBA2 gene carried out using primers HBA_F1 with 
HBA_R3 and HBA_F2 with HBA_R2, which resulted in products of 541 bp and 
593 bp, respectively.  
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All PCRs of the a-globin genes were performed on a 9700 Thermocycler (Applied 
Biosystems, USA) using Platinum Taq Polymerase in PCR Buffer (Invitrogen) 
containing 2.0 mM MgCl2 and 1.2 M betaine. The PCR included 10 minutes at 
95oC and 45 cycles of 95 oC for 20 seconds, 58 oC for 20 second and 72 oC for 1 
minute. 
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Table 14: Primers for sequencing the HBA1 and HBA2 genes 
Primer Direction Target Primer sequence (5’ to 3’) 
HBA_F1 Forward HBA1 and HBA2 GCTCCGCGCCAGCCAAT 
HBA_R1 Reverse HBA1 CTGCTGTCCACGCCCAT 
HBA_F2 Forward HBA1 and HBA2 CCCAGGTTAAGGGCCACG 
HBA_R2 Reverse HBA2 ACACCTCCATTGTTGGCACAT 
HBA_R3 Reverse HBA1 and HBA2 GGTCCACCCGAAGCTTG 
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4.3.5 Amplicon generation for sequencing the HBB gene 
Amplicons for sequencing the HBB gene were generated using the primers in 
Table 15. Each 10 µl HRM-PCR reaction included 5 µL of LightCycler 480 High 
Resolution Melting Master, 3.75 mM MgCl2, 25 ng of genomic DNA and 0.2 µM 
of each primer. After a 10 minute hold at 95 oC, 45 cycles of PCR were performed 
as follows: 15 s at 95 oC, 15 s annealing at the temperature given in Table 15, 
and extension at 72 oC for the time given in Table 15. Cycling was followed by a 
5 minutes hold at 72 oC. 
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Table 15: Primers used to generate amplicons for sequencing the HBB 
gene and Gap-PCR to detect the Filipino β-thalassaemia deletion 
Target Direction Primer sequence (5’ to 3’) 
Position on 
reference 
sequence  
Product 
Length 
 (bp) 
Anneal 
Temp 
(oC) 
Extension 
time (sec) 
HBB Exon 1 
and 2 
Forward TGTCATCACTTAGACCTCACCCTG 5,226,544 to 
5,227,193 on 
NC_0000.11.10 
686 58 40 
Reverse GGAAAGAAAACATCAAGCGTCCCATAG 
HBB 
Intervening 
sequence 2 
Forward TGCACGTGGATCCTGAGAACTTCA 5,226,411 to 
5,226,602 on 
NC_000011.10 
228 56 20 
Reverse ACAGCAAATAAAAGAAACTAAAACGA 
HBB Exon 3 
Forward GCTGGATTATTCTGAGTCCAAGCTA 5,225,508 to 
5,225,797 on 
NC_000011.10 
326 58 25 
Reverse TCAAGGCCCTTCATAATATCCCC 
GAP-PCR 
Filipino β-
thalassaemia 
deletion 
Forward GTAAATGAGTAAATGAAGGAATGAT 5,112,653 to 
5,232,062 on 
NC_000011.10 
920 60 60 
Reverse TGTGATTTGGCTCTCTTCTTGTCTA 
 
The primers used to generate amplicons for sequencing the HBB gene are shown along with 
the appropriate PCR reaction conditions. The sequencing primers were synthesized with M13 
tails (not shown). Primers used for the detection of the Filipino β-thalassaemia deletion by Gap-
PCR are also shown (synthesized without M13 tails).  
Table from Turner et al. 2016 BMC Medical Genetics, 17:75 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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4.3.6 Gap-PCR for the detection of the Filipino b-thalassaemia deletion 
(NG_000007.3:g.66258_184734del118477) 
The Filipino β-thalassaemia deletion was confirmed by Gap-PCR as previously 
described (Yamashiro et al. 2012). Each 12.5 µL PCR reaction included 0.25 
units of Platinum Taq, 1x PCR buffer (Invitrogen), 0.3 mM of each dNTP, 2.0 mM 
MgCl2, 0.1 µM of each primer (Table 15) and 25 ng of genomic DNA. After an 
initial 4 minute hold at 94 oC, 38 cycles of PCR was performed as follows: 30 s at 
94 oC, 30 s at 60 oC, 60 s at 72 oC. PCR products were evaluated by 
electrophoresis using 1% agarose gels, with detection of a 920 bp product 
indicating the presence of the 118 kb deletion.  
 
4.3.7 Confirmation of the HBB 619 base pair deletion (NM_000518.4:c.316-
149_*342delinsAAGTAGA) 
The presence of the HBB 619 bp deletion was confirmed using the CE-IVD 
(Conformité Européene - In Vitro Diagnostics) marked b-Globin StripAssay 
(ViennaLab Diagnostics, Austria) in accordance with the manufacturer’s 
instructions. 
4.3.8 a-Globin genotyping 
a-Globin genotyping was performed using the CE-IVD marked a-Globin 
StripAssay (ViennaLab Diagnostics) in accordance with the manufacturer’s 
instructions. The StripAssay is able to detect the aaaanti 3.7 duplication and the 
following deletions: -a3.7, -a4.2, -(a)20.5, --SEA, --Med, --Fil, --Thai in addition to a 
number of point mutations including aConstant Springa, aIcariaa, apolyA-1a and apolyA-2a.   
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4.4 Sequencing methods 
4.4.1 Cycle sequencing 
PCR products for sequencing were diluted 1:150 with RNAse free distilled water 
prior to cycle sequencing. Cycle sequencing was performed on a 9700 
thermocycler (Applied Biosystems, USA) using the BigDye Terminator v3.1 Cycle 
Sequencing kit (Applied Biosystems). 
For sequencing of the HBB gene, each reaction contained; 4µL BigDye Ready 
Reaction Premix, 2 µL BigDye Sequencing Buffer, 0.2 µM of primer, 4 µL of 
diluted template and water to make up the final volume to 20 µL. For sequencing 
the HBA1 or HBA2 genes the cycle sequencing setup was the same, except that 
1 M betaine was included.  
For the HBB gene, after a one minute hold at 96 oC, 25 cycles of were performed 
as follows; 10 s at 96 oC, 5 s at 50 oC and 240 s at 60 oC. Cycling conditions for 
the HBA1 or HBA2 genes were the same, except that the number of cycles was 
increased to 50. 
 
4.4.2 Cleaning of cycle sequencing products 
Cycle sequencing products were cleaned by ethanol / EDTA precipitation in 96 
well reaction plates using the Applied Biosystems protocol. 
After cycle sequencing 5 µL of 125 mM EDTA and 60 µL of 100% ethanol was 
added to each 20 µL sequencing reaction. After sealing with aluminium foil and 
mixing by inversion, the plates were incubated at room temperature for 15 
minutes. The plates were then centrifuged at 3000 g for 30 minutes, prior to being 
inverted and flicked to remove most of the liquid. The inverted plates were then 
spun briefly up to 185 g over blotting paper to remove any remaining liquid. Sixty 
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µL of ice cold 70% ethanol was added to each well and the plate was spun at 
1650 g for 15 minutes. After inverting and spinning briefly to 185 g the plates were 
allowed to air dry for 30 minutes before the addition of 10 µL of HiDi Formamide 
(Applied Biosystems). Finally, the plate was heated to 95 oC for 2 minutes and 
allowed to cool to room temperature before sequencing. 
 
4.4.3 Sequencing 
Sequencing was performed on a 3130 genetic analyser (Applied Biosystems) 
using POP7 polymer (Applied Biosystems) and a 36 cm capillary array.  
Analysis of the sequencing results was performed using Sequence Analysis 
Software version 5.3.1 (Applied Biosystems). 
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5.0 Development and validation of a high throughput, closed tube 
method for the determination of haemoglobin alpha gene (HBA1 and HBA2) 
numbers by Gene Ratio Assay Copy Enumeration PCR (GRACE-PCR) 
 
5.1 Introduction 
a-Thalassaemia is a very common genetic disorder, with the vast majority of 
cases arising as the result of large deletions that affect one or both of the a-globin 
genes. Diagnosis of asymptomatic carriers can only be reliably achieved through 
the use of molecular techniques (Harteveld & Higgs 2010).  However, the 
molecular diagnostic techniques currently available for the detection of a-globin 
gene deletions are relatively labour intensive and thus not particularly well suited 
to high throughput screening.   Consequently, there is a need for a rapid and 
reliable molecular method for the diagnosis of deletional a-thalassaemia. 
A novel technique based on co-amplification of a target and a reference gene, 
followed by melting analysis has been described for copy number determination 
of the Adenomatous Polyposis Coli (APC) gene (Torrezan et al. 2012), the Ataxia 
telangiectasia mutated serine / threonine kinase (ATM) gene (Koboldt et al. 2014) 
and the Dystrophin (DMD) gene (Borun et al. 2014). Here a similar approach is 
utilised to develop a PCR technique for the simultaneous determination of copy 
numbers for both the HBA1 and HBA2 genes. The resulting assay can be 
performed in a single closed tube and is well suited as a screening test for the 
deletional forms of a-thalassaemia. 
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5.2 Samples and methods 
5.2.1 Samples 
This study was conducted using anonymous, archived material from blood 
specimens submitted to the Sheikh Khalifa Medical City (SKMC) laboratory, Abu 
Dhabi, United Arab Emirates for haemoglobinopathy screening. Ethical clearance 
was obtained from the SKMC Institutional Research and Ethics Committee to use 
this material for the current study. In total 167 samples were used.  
The performance characteristics of the GRACE-PCR assay were originally 
established using 105 samples with known genotype. These samples were 
selected to represent as many different a-globin genotypes as possible. Samples 
with point mutations of the HBA2 gene in the stop codon or untranscribed region 
(UTR) were also included to assess their impact on assay performance. The 
assay was further validated using an additional 62 samples of unknown 
genotype. 
 
5.2.2 Methods 
DNA extraction – see section 4.1 
Primer design and synthesis – see section 4.21  
GRACE-PCR – see section 4.3.1 
GRACE-PCR with alternative primers – see section 4.3.2 
a-Globin genotyping – see section 4.3.8 
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5.3 Results 
5.3.1 GRACE-PCR design and optimization 
Initially, Platinum Taq polymerase was used in combination with 1.2 M betaine 
during the development of the GRACE-PCR assay. This strongly favoured the 
amplification of HBA2 over HBA1, which made the quantification of the latter 
difficult in a single tube multiplex assay. This issue could not be resolved by a 
simple redesign of the primers. Consequently, an assay was developed using 
two separate PCR reactions, one to quantify the HBA1 gene and a second to 
quantify the HBA2 gene (Figure 18). Subsequently, various alternative enzymes 
and enhancers were tried and with the use of an enzyme cocktail containing 
Platinum Taq and Kappa HiFi HotStart polymerases simultaneous and 
comparable amplification of HBA1 and HBA2 was achieved. This allowed the 
development of an improved version of the GRACE-PCR assay with 
quantification of both the HBA1 and HBA2 genes from a single PCR tube (Figure 
19). The Kappa HiFi HotStart polymerase has 3’ to 5’ exonuclease proofreading 
activity, thus to avoid miss-priming of the HBA2 forward primer to HBA1 a 
phosphorothioate (PTO) block was incorporated in the primer sequence (Table 
12) (Skerra 1992). The size and purity of the products was confirmed using 
agarose gel electrophoresis (Figure 20). Amplification of the CLCN7 control gene 
(Fallah et al. 2010; Babashah et al. 2009) was more efficient than that of the 
target a-globin genes, which was corrected by reducing the concentration of the 
CLCN7 primers. Limiting the number of PCR cycles resulted in termination of 
amplification during the exponential phase of the PCR reaction. This ensured that 
the relative amount of each PCR product remained proportional to the initial 
number of copies of the gene present.  
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Figure 18: A two tube GRACE-PCR assay for the determination of a-globin gene copy 
numbers. Limiting the PCR to 27 cycles stops amplification in the exponential phase ensuring 
that the relative amounts of each product is proportional to initial DNA quantity (Panel A). The 
peak height (-dF/dT) relative to the reference gene allows the copy number for the target gene to 
be determined. Tube 1 quantifies the HBA1 gene (Panel B). Tube 2 quantifies the HBA2 gene 
(Panels C and D).  
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Figure 19: Single tube GRACE-PCR assay targeting both a-globin genes (HBA1 and HBA2) 
and a reference gene (CNCN7). Peak height, relative to the reference gene, in the melting plots 
(–dF/dT versus temperature) is proportional to the copy number of each gene (indicated in 
parenthesis under the gene name). Four genotypes with varying a-globin gene copy numbers are 
shown in plots A to D.  
Figure from Turner et al. 2015 BMC Medical Genetics, 16:115 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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Figure 20: Agarose gel electrophoresis of the GRACE-PCR primer products.  The expected 
size of each PCR product is indicated in parenthesis.   
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5.3.2 Data analysis 
The amount of PCR product from each of the three genes targeted in the GRACE-
PCR assay is proportional to the height of the peak on the -dF/dT versus 
temperature plots (Figure 19). Initially, gene copy numbers were determined by 
measuring peak heights on the -dF/dT plots (Figure 19) and then normalising the 
data to a wild type control sample included in the same run using the following 
calculation: Normalised ratio = (RWT Control / TWT Control) / (RUnknown / TUnknown); where 
R and T are the peak heights for the reference (CLCN7) and the target (HBA1 or 
HBA2) genes, respectively. The subscript ‘WT Control’ indicates the wild type 
control sample. This process worked well and allowed the correct copy number 
for both a-globin genes to be determined for all samples tested (Table 16 and 
Figure 21). However, this method of data analysis was time consuming. 
Consequently, a simplified visual method for data analysis was developed, which 
utilized features available in the HRM module Rotor-Gene Q series software 
(Figure 22) and eliminated the need for manual calculations.  
	 90	
Table 16: Genotypes of samples used in the development and validation of 
the alpha globin gene ratio assay copy enumeration PCR (GRACE-PCR). 
a-Globin StripAssay  GRACE-PCR Screening Test 
Genotype Strip 
Assay 
(n) 
PCR 1 
(n) 
 
PCR 2 
(n) 
CLCN7:
HBA1 
Ratio 
HBA1:
HBA2 
Ratio 
HBA1 
Copies  
HBA2 
Copies 
1. aa/aa (wild type) 54 30 24 1:1 1:1 2 2 
2. aa/-a3.7 48 29 19 1:1 2:1 2 (a) 1 
3. -a3.7/-a3.7 36 20 16 1:1 1:0 2 (a) 0 
4. aa/-a4.2 2 2 0 1:1 2:1 2 1 
5. -a4.2/-a4.2 1 1 0 1:1 1:0 2 0 
6. -a3.7/-a4.2 3 3 0 1:1 1:0 2 (a) 0 
7. -a3.7/--SEA 6 3 3 2:1 1:0 1 (a) 0 
8. aa/--Med 2 2 0 2:1 1:1 1 1 
9. aa/--Fil 2 2 0 2:1 1:1 1 1 
10. -(a)20.5 1 1 0 1:1 2:1 2 (b) 1 
11. aa/aaaanti 3.7 2 2 0 1:1 2:3 2 3 
12. -a3.7/aIcariaa (c) 1 1 0 1:1 2:1 2(a) 1 
13. aa/apoly-A1a (c) 2 2 0 1:1 1:1 2 2 
14. aa/apoly-A2a (c) 1 1 0 1:1 1:1 2 2 
15. -a3.7/apolyA1a (c) 4 4 0 1:1 2:1 2 (a) 1 
16. aa/aConstant Springa (c) 1 1 0 1:1 1:1 2 2 
17. aConstant Springa/aConstant Springa (c) 1 1 0 1:1 1:1 2 2 
Total number of samples 167 105 62  
 
The GRACE-PCR assay was assessed using samples with previously determined (PCR1) and 
unknown (PCR 2) genotypes. GRACE-PCR was able to detect all 108 samples identified by the 
commercial a-globin StripAssay as having a-globin gene copy number variations (genotypes 2 to 
12 and 15). 
(a) Due to the positioning of primers at the 3’ ends of the a-globin genes, the hybrid -a3.7 
gene is counted as an HBA1 gene in this assay. 
(b) The -(a)20.5 deletion does not extend to the 3’ end on the HBA1 gene targeted by the 
GRACE-PCR screening test primers, consequently only the deletion of the HBA2 gene 
is detected. 
(c) Samples with point mutations (genotypes 12 to 17) were included to ensure that these 
point mutations did not affect the gene-copy number determination of the GRACE-PCR 
assay.  
Table from Turner et al. 2015 BMC Medical Genetics, 16:115 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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Figure 21: Normalised ratios of -dF/dT peak heights for different copy numbers of the HBA1 
and HBA2 genes. The horizontal bars indicate the mean ratio and the vertical bars indicate the 
range from the minimum to maximum ratio observed for each gene copy number.  The data was 
normalised with the equation:  
Normalised ratio = (RWT Control / TWT Control) / (RSample / TSample) 
Where R and T is reference gene and target gene peak heights, respectively. 
Figure from Turner et al. 2015 BMC Medical Genetics, 16:115 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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As expected in the GRACE-PCR assay three distinct melt transition steps could 
be observed in the melting curves corresponding to the melting temperatures of 
the PCR products initially designed to be 3oC apart (Figure 22A, Table 12). 
Therefore, these steps could be assigned to the melting of the products from 
CLCN7, HBA1 and HBA2 genes as indicated in Figure 22A. Normalisation of the 
raw HRM data was performed in two stages using the Rotor-Gene Q series 
software. Firstly, normalisation ranges were set before the melting of the CLCN7 
product and after the melting of the HBA1 product (normalisation ranges N1 and 
N2 indicated by the dark grey bars in Figure 22). This resulted in a plot in which 
the height of the curve between the CLCN7 and HBA1 melt regions is dependent 
on the gene copy number ratio of CLCN7:HBA1. Inclusion of a known wild type 
control sample in each run allowed rapid visual determination of any samples with 
abnormal copy numbers for HBA1 (Figure 22B). Since the number of copies of 
the CLCN7 reference gene is assumed to be two, this ratio can be used to 
determine the copy number for the HBA1 gene. In the second stage of the 
analysis normalisation ranges were set before the melting of the HBA1 product 
and after the melting of the HBA2 product (using the normalisation ranges N3 
and N4 indicated by the light grey bars in Figure 22). This resulted in a plot 
allowing the gene copy number ratio of HBA1:HBA2 to be determined (Figure 
22C). Since the copy number for the HBA1 gene was already determined in the 
first stage of the analysis this ratio allowed the copy number for HBA2 to be easily 
derived. This alternative visual method of analysis led to identical results as the 
more complex calculation method for all 167 samples included in the study, but 
proved far quicker and simpler to perform. 
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Figure 22: Normalisation of GRACE-PCR data to allow visual determination of gene copy 
numbers – see following page for legend 
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Legend for Figure 22 (previous page): Raw melting curves show three distinct steps 
corresponding to the melting of the CLCN7, HBA1 and HBA2 gene products generated during 
the GRACE-PCR (A). Setting the normalisation regions N1 and N2 (dark grey bars) in the HRM 
analysis software allowed the gene copy number ratio for CLCN7:HBA1 to be determined (B). 
Re-setting the normalisation regions to N3 and N4 (light grey bars) allowed the determination of 
the gene copy number ratio HBA1:HBA2 (C). The copy number for CLCN7 is assumed to be two, 
which allows the number of HBA1 copies to be calculated (B), which in turn allows the 
determination of the number of HBA2 copies.  
Figure from Turner et al. 2015 BMC Medical Genetics, 16:115 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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5.3.3 Assessment and validation of GRACE-PCR assay 
An initial assessment of the assay was carried out using 105 samples that had 
been previously genotyped with the commercial a-Globin StripAssay. These 105 
samples included 70 samples that had deletions or duplications of one or more 
of the a-globin genes. Samples with mutations of the HBA2 stop codon and UTR 
were also included to ensure that they did not interfere with the assay 
performance. 
GRACE-PCR correctly identified the 70 samples shown by the a-globin 
StripAssay to have deletions or duplications of the a-globin genes (Table 16). 
Mutations of the stop codon or UTR did not affect the copy number result, 
however the -(a)20.5 deletion (Figure 16) was detected as a deletion of the HBA2 
gene only. This was because the -(a)20.5 deletion removes all of the HBA2 gene 
and the 5’ end of the HBA1 gene, but does not extend to the primer target at the 
3’ end of the HBA1 gene. The performance of the GRACE-PCR assay was further 
validated by the analysis of an additional 62 samples prior to genotyping by the 
a-globin StripAssay. GRACE-PCR detected a-globin gene deletions in 38 of 
these samples, all of which were subsequently confirmed by genotyping (Table 
16). Additionally, 143 samples were analysed using alternative primers (Table 
12), the results were consistent with those obtained in the initial GRACE-PCR 
screen and no allele drop out was observed (Table 17 and Figure 23). 
In total 108 of the samples were identified by the a-globin StripAssay as having 
a deletion or duplication of the a-globin genes. GRACE-PCR returned abnormal 
a-globin gene copy numbers for all 108 positive samples and did not generate 
any false positives (Table 16). This equates to a sensitivity of 100.0% (95% 
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confidence interval 96.6-100.0%) and a specificity of 100.0% (95% confidence 
interval 93.9-100.0%).  
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Table 17: Comparison of results obtained by GRACE-PCR using both the 
original and alternative primers. 
 
Genotype  
(from commercial StripAssay) 
Samples 
(n) 
HBA2 Copies 
(Original primers) 
HBA2 Copies 
(Alternative primers) 
1. aa/aa (wild type) 40 2 2 
2. aa/-a3.7 48 1 1 
3. -a3.7/-a3.7 30 0 0 
4. aa/-a4.2 2 1 1 
5. -a4.2/-a4.2 1 0 0 
6. -a3.7/-a4.2 3 0 0 
7. -a3.7/--SEA 3 0 0 
8. aa/--Med 2 1 1 
9. aa/--Fil 2 1 1 
10. -(a)20.5 1 1 1 
11.aa/aaaanti 3.7 1 3 3 
12. -a3.7/aIcariaa 1 1 1 
13. aa/apoly-A1a 2 2 2 
14. aa/apoly-A2a 1 2 2 
15. -a3.7/apolyA1a 4 1 1 
16. aa/aConstant Springa 1 2 2 
17. aConstant Springa/aConstant Springa 1 2 2 
Total 143   
 
The alternative GRACE-PCR primers were tested with 143 samples. For all samples, the HBA2 
copy numbers obtained with the alternative primers were consistent with the results obtained 
using the original GRACE-PCR primers. 
Table from Turner et al. 2015 BMC Medical Genetics, 16:115 – supplementary data (Creative 
Commons Licence http://creativecommons.org/licenses/by/4.0/). 
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Figure 23: Normalisation of the GRACE-PCR data obtained with the alternative primers. 
The raw melting curves show two distinct steps corresponding to the melting of the CLCN7, and 
HBA2 gene products generated during the GRACE-PCR (A). Setting the normalisation regions 
N1 and N2 (grey bars) in the HRM analysis software allowed the gene copy number ratio for 
CLCN7:HBA2 to be determined (B). The copy number for CLCN7 is assumed to be two, which 
allows the number of HBA2 copies to be calculated (B). 
Figure from Turner et al. 2015 BMC Medical Genetics, 16:115 – supplementary data (Creative 
Commons Licence http://creativecommons.org/licenses/by/4.0/). 
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5.4 Discussion 
Conventional Gap-PCR and reverse hybridization assays are commonly used 
methods to detect a-globin gene deletions (Chong et al. 2000; Tan et al. 2001; 
de Mare et al. 2010; Liu et al. 2000). These techniques are reliable and allow 
identification of the specific targeted gene deletions. However, Gap-PCR is not 
ideal for high volume testing in a clinical laboratory, since it is relatively time 
consuming and labour intensive.  
PCR protocols for Gap-PCR require a long extension step in order to generate 
fairly large amplicons; consequently, PCR cycling is slow and typically takes 
approximately 3 hours. The subsequent detection by agarose gel electrophoresis 
involves considerable hands on time, adding around another 2 hours to the 
analysis. In common with Gap-PCR reverse hybridization assays are open tube 
techniques that take several hours to complete. In contrast, GRACE-PCR takes 
approximately two hours to complete with no further hands on time required after 
the initial reagent setup. Thus, while the consumable costs for GRACE-PCR are 
similar to Gap-PCR, there is a significant saving in labour. Therefore, a stepwise 
clinical laboratory investigation incorporating a rapid screening step of a-globin 
gene deletions has been suggested to be a more efficient approach (Alkindi et al. 
2013). In the proposed workflow here for the detection of a-globin gene deletions, 
all samples are first screened by the rapid and inexpensive GRACE-PCR assay, 
and then those identified with a variant copy number can optionally be analysed 
further with a different method that can identify the specific genotype. The initial 
GRACE-PCR step in this workflow has the additional advantage that it can detect 
gene copy number variations results from novel deletions or duplications which 
would not be identified by other assays, for example Gap-PCR. 
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A single wild type sample was used as a control with each GRACE-PCR run. 
While this proved sufficient for research purposes, the inclusion of additional 
control samples with known abnormal a-globin gene numbers would be highly 
recommended when the assay is used in the clinical setting. 
Multiplex Ligation-dependent Probe Amplification (MLPA), can be used for the 
detection of deletions for which the breakpoints are not know (Lee et al. 2009; 
Phylipsen et al. 2010; Colosimo et al. 2011). MLPA allows mapping of the 
approximate breakpoints, but the technology is too time consuming and complex 
to be used for routine diagnostics. More recently Next Generation Sequencing 
has also been used to detect deletions of the globin genes. Short read lengths 
mean that NGS is not inherently well suited to the task of detecting large gene 
rearrangements, but it is possible through careful analysis with appropriate 
bioinformatics software (Wu et al. 2016; Clark et al. 2017). As with MLPA, NGS 
provides information about the breakpoints but the need for library preparation 
makes this technique too time consuming to be used for routine clinical 
investigations.   
Fragment analysis by capillary electrophoresis has also been used to determine 
a-globin gene copy numbers (Liao et al. 2012; Mo et al. 2012; Alkindi et al. 2013; 
Turner et al. 2014). These assays make use of the eight base pairs length 
difference between the HBA1 and HBA2 genes. One limitation of these assays is 
that due to rearrangements of the a-globin genes, such as the African a2 
Polymorphism or the a12 allele (HBA2:c.301-24delGinsCTCGGCCC), this 
difference in length between the HBA1 and HBA2 genes can be absent (Segbena 
et al. 1998; Law et al. 2006; Borgio et al. 2014; Pang et al. 2016). Indeed, these 
polymorphisms are reported to be very common, with frequencies ranging from 
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0.36% in China (Pang et al. 2016), 5.7% in Saudi Arabia (Borgio 2015) and up to 
12% in some African populations (Segbena et al. 1998). In contrast, GRACE-
PCR is not affected by these gene rearrangements and it does not require the 
use of a capillary electrophoresis based genetic analyser, making it a more 
universally applicable and faster screening method. 
In common with fragment analysis by capillary electrophoresis the GRACE-PCR 
assay used a limited number of cycles in order to terminate the reaction in the 
exponential phase; this is an established method of ensuring that the ratios of the 
PCR products remain proportional to the initial amounts of DNA present 
(Castellsague et al. 2008; Noutsias et al. 2008; Borun et al. 2014). An alternative 
approach of limiting the dNTPs concentration has also been described (Zhou et 
al. 2015). The authors claim that limiting dNTPs concentration simplifies assay 
design since it is not necessary to conduct experiments to determine the correct 
number of PCR cycles, however it is still necessary to determine the 
concentration of dNTPs by titration. Consequently, it is not clear if this approach 
offers any advantage over simply limiting the number of PCR cycles. One 
possible disadvantage of limiting the dNTPs concentration is that it would 
preclude the use of standard commercial master mixes.  
As with most PCR based techniques, GRACE-PCR could potentially yield 
incorrect results due to a SNP within a priming site inhibiting primer annealing 
and therefore causing allele dropout. The 5’ end of the reverse primer for HBA2 
coincided with the stop codon and consequently, there was a risk that mutations 
of this codon might result in allele dropout. This was tested by including samples 
from individuals carrying a mutation in the stop codon, Hb Constant Spring 
(HBA2:c.427T>C) and Hb Icaria (HBA2:c.427T>A), in the assay validation. The 
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assay design proved to be robust and the presence of the mutations of the HBA2 
stop codon did not result in allele dropout (Table 16, Genotypes 12, 16 and 17).  
Some other low frequency SNPs have also been described within the GRACE-
PCR priming sites, the most frequent of which (rs2261869) has a minor allele 
frequency (MAF) of T=0.0016 (Sherry et al. 2001). Thus, the possibility of allele 
dropout needs be considered if GRACE-PCR gives an unexpected result that 
cannot be confirmed by Gap-PCR. One possibility for checking the original 
GRACE-PCR screening result is the use of alternative primers for HBA2 and 
CLCN7 (Table 12, Figure 23) before proceeding to more complex tests such as 
MLPA. In the current study, all results of the ‘original’ and ‘alternate’ GRACE-
PCRs were consistent with the genotype from the StripAssay indicating that no 
allele dropout had occurred, suggesting that such events should be rare.  
The impact that point mutations might have on the performance of GRACE-PCR 
was also considered. Point mutations may alter the melt curve shapes, but would 
have a negligible impact on total fluorescence, which is dependent on the 
amplicon amount produced. Consequently, point mutations are not expected to 
have a significant impact on copy number determination, since GRACE-PCR 
interpretation is dependent on the fall in fluorescence as each amplicon melts. 
Indeed, inclusion of samples with the aPoly A1 (HBA2:c.*92A>G) and aPoly A2 
(HBA2:c.*94A>G) mutations in the method validation confirmed that point 
mutations within the amplicons did not affect the result interpretation (Table 16, 
Genotypes 13 to 15).  
Other melt curve based methods have been previously described for the 
detection of a-globin gene deletions. Most of these are modified Gap-PCR 
assays that use melting curve analysis as means of detection, thus eliminating 
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the need for agarose gel electrophoresis (Pornprasert et al. 2008; Liu et al. 2010; 
Munkongdee et al. 2010; Seeratanachot et al. 2013). This makes them more 
convenient than conventional Gap-PCR, but they have only been developed for 
a limited set of deletions such as --SEA and --THAI (Pornprasert et al. 2008). A melt 
curve method that compares ratios of HBA1 and HBA2 gene PCR products has 
also been described, but this method did not include a reference gene and thus, 
required additional tubes to detect certain genotypes (Munkongdee et al. 2010). 
The simplicity of quantitative PCR (qPCR) makes it an attractive technology for 
copy number determination and methods for the a-globin genes have previously 
been described (Sangkitporn et al. 2003; Fallah et al. 2010; Zhou et al. 2013; 
Grimholt et al. 2014; Seeratanachot et al. 2015; Long 2016). However, current 
qPCR assays either amplify the reference gene and each target gene in separate 
tubes (Sangkitporn et al. 2003; Fallah et al. 2010; Seeratanachot et al. 2015), or 
require the use of labelled probes, which increases reagent costs (Zhou et al. 
2013; Grimholt et al. 2014; Long 2016). Thus, such assays are less convenient 
than the GRACE-PCR screening test, which can be performed in a single tube 
without the need for probes.  
In common with GRACE-PCR, both fragment analysis by capillary 
electrophoresis and qPCR quantify the a-globin genes relative to a reference 
gene that is assumed to have a copy number of two. The current GRACE-PCR 
assay used the well characterized CLCN7 gene for reference (Waguespack et al. 
2007; Babashah et al. 2009; Fallah et al. 2010). This gene is well suited for this 
application because it has no pseudo-genes (Fallah et al. 2010) and mutations 
lead to autosomal dominant osteopetrosis, an uncommon sclerosing bone 
disorder (Waguespack et al. 2007). Consequently, individuals without obvious 
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bone abnormalities are expected to have two intact copies of the gene. There is 
a common SNP (rs2744995, MAF G=0.3808) at the ultimate 5’ base of the 
GRACE-PCR CLCN7 gene reverse primer. Due to its location at the 5’ end of the 
primer this SNP would not be expected to affect the assay results. Indeed, 
CLCN7 copy numbers were identical when alternative primers were used (Table 
17). No information was available on bone abnormalities for the archived material 
used in the current study, but consistency between the GRACE-PCR and the 
StripAssay results indicated that all subjects included in the study had two copies 
of the CLCN7 gene and neither rs2744995 nor any other SNPs that may have 
been present affected the results (Table 16). Additionally, in most cases copy 
number changes or miss-priming of the CLCN7 reference gene would result in 
an improbable HBA1 copy number highlighting such samples for further 
investigation.  
A limitation of copy number determination methods is that the presence of 
deletions or duplications is inferred from the total number of genes, rather than 
detected directly. When an individual co-inherits both a deletion and duplication 
of a gene, the total number of genes does not change and consequently such 
cases would appear normal. For example, the genotype -a3.7/aaaanti3.7 has the 
same number of a-globin genes as aa/aa and thus these genotypes cannot be 
distinguished by gene copy number. This limitation applies equally to GRACE-
PCR, qPCR, capillary electrophoresis fragment analysis and to MLPA. Such 
combinations would be rare and would not affect the phenotype of the individual 
carrying the mutations.  
Copy number based assays do not provide the identity of the specific deletions / 
duplications detected. However, the GRACE-PCR assay does differentiate 
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between cases with two alleles carrying a+ deletions (-a/-a) from cases with a 
single ao deletion (aa/--). This clinically important distinction can be made 
because the assay uses targets at the 3’ end of each a-globin gene. The 
advantage of this approach is that the -a3.7 hybrid allele types as an HBA2 gene 
deletion, thus allowing compound heterozygotes -a3.7/-a4.2 to be distinguished 
from a single large ao deletion (aa/--). An assay that utilized targets 5’ of the a-
globin genes could make this distinction.  
Finally, assays based on DHPLC have been described to detect the 
common -a3.7, -a4.2 and --SEA deletions (Hung et al. 2007; Liu et al. 2010). DHPLC 
requires a specialized chromatography system for detection and the post 
amplification processing takes around 10 minutes for each sample. The GRACE-
PCR assay has a detection step that is far more rapid, taking around 10 minutes 
for a batch of 72 samples. Furthermore, with the use of a plate based PCR system 
GRACE-PCR batch sizes could be increased up to 384 samples without 
increasing the post amplification processing time.  
In conclusion, the GRACE-PCR test described here is a simple and robust 
method for simultaneous copy number assignment of both the HBA1 and HBA2 
genes. This method is well suited for rapid initial screening of a large number of 
samples since: (1) unlike Gap-PCR, DHPLC and capillary electrophoresis based 
methods it does not require extensive post-amplification processing of samples 
(i.e. electrophoresis or chromatography); (2) in contrast to fragment analysis by 
capillary electrophoresis-based assays it does not require the use of a capillary 
electrophoresis based genetic analyser and is not affected by the common 
African a2 polymorphism; (3) in this closed tube assay the risk of amplicon 
contamination is negligible; and (4) the data analysis is very simple and allows 
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instant visual identification of any samples in a batch with abnormal a-globin gene 
copy numbers. 
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6.0 Rapid detection of pathological mutations and deletions of the 
haemoglobin beta gene (HBB) by High Resolution Melting (HRM) analysis 
and Gene Ratio Assay Copy Enumeration PCR (GRACE-PCR) 
 
6.1 Introduction 
To date, a total of 873 pathological mutations of the HBB gene have been 
described (Hbvar 2017). This level of genetic diversity limits the usefulness of 
traditional PCR based diagnostic techniques, which target a single mutation, or 
small group of mutations. In such situations, gene scanning by HRM-PCR is a 
potentially attractive alternative approach, since it has proved to be a robust, high 
throughput method that has been successfully applied to numerous clinical 
applications (Erali et al. 2008).  
Various HRM-PCR assays targeting the HBB gene have been described (Shih et 
al. 2009; Saetung et al. 2013; Lin et al. 2014; Prajantasen et al. 2015; 
Chassanidis et al. 2016), however the clinical usefulness of these assays is 
limited by two key factors. Firstly, these assays have little or no ability to detect 
larger gene deletions and secondly the approaches used to handle certain high 
frequency SNPs results in these assays being unable to detect some clinically 
important mutations.  
The purpose of the current study was to develop and validate an alternative assay 
that addressed the issues of SNP interference and the detection of deletions 
while retaining the advantages of HRM-PCR. 
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6.2 Samples and methods 
6.2.1 Samples 
This study was conducted using anonymous, archived material from blood 
specimens submitted to the SKMC laboratory, Abu Dhabi, United Arab Emirates 
for haemoglobinopathy screening. Ethical clearance was obtained from the 
SKMC Institutional Research and Ethics Committee to use this material for the 
current study. The material used contained no patient identifiers, but the results 
of the haemoglobin analysis by HPLC had been assigned prior to the 
anonymisation of samples. A total of 410 samples were used in the study, these 
included 305 with elevated Hb A2 (Hb A2 > 3.5%), 27 with low or normal Hb A2, 
76 with abnormal haemoglobins and two samples known to be positive for the 
619 base pair deletion (NM_000518.4:c.316-149_*342delinsAAGTAGA) 
(Pritchard et al. 2010). The initial assessment of the assay was conducted using 
342 of these samples and the additional 68 were used for a blinded validation. 
 
6.2.2 Methods 
DNA extraction – see section 4.1 
Primer design and synthesis – see section 4.2.2 
HBB gene GRACE-PCR – see section 4.3.3 
HBB gene sequencing – see sections 4.3.5 and 4.4 
Gap-PCR to detect the Filipino deletion – see section 4.3.6 
Confirmation of the 619 bp deletion – see section 4.3.7 
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6.3 Results 
6.3.1 Amplicon and primer design 
The final version of the assay used a total of 13 primer pairs, which generated 
products ranging in size from 82 bp to 158 bp (Table 13 and Figure 24). When a 
common non-pathological SNP was present in a region that was optimal for 
primer placement, the nucleotide at the SNP position was substituted with the 
universal base inosine. Incorporating inosine into the primer allows equal 
amplification of both the wild-type and variant alleles (Hondow et al. 2011). This 
proved to be a good strategy for eliminating SNP interference and resulted clear 
HRM-PCR profiles that were highly reproducible both within and between runs 
(Figure 25). The SNPs concerned were rs10768683 (HBB:c.315+16G>C) under 
the reverse H6 primer and rs1609812 (HBB:c.316-185C>T) under the reverse H7 
primer (Table 13). An example showing the detection of the HBB:c.315+1G>A 
mutant and wild type alleles where inosine in the primer was used to mask the 
non-pathological SNP rs10768683 is shown in Figure 25, plots 1A and 1B, and 
Table 18 (genotype 37). 
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Figure 24: HBB assay PCR products. Agarose gel electrophoresis showing the relative sizes 
of the 13 PCR products generated in the assay used to detect point mutations and deletions of 
the HBB gene. The expected size of each PCR product is indicated in parenthesis. Details of the 
primers used are given in Table 13. 
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Figure 25: Representative HRM-PCR difference plots. Difference plots show wild type 
samples and the various mutants: 1A&B – genotype 37; 2A&B – genotype 28; 3A&B – genotype 
33; 4A&B – genotype 2; 5A&B – genotypes 24 and 18 (see Table 18). Plots 1A&B were generated 
using primer pair 6 containing the universal base inosine (Table 13). Panels A and B show 
different runs with different samples. Figure from Turner et al. 2016 BMC Medical Genetics, 17:75 
(Creative Commons Licence http://creativecommons.org/licences/by/4.0/). 
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Table 18: Mutations of the HBB gene detected HRM-PCR and GRACE-PCR 
 
 Genotype  
Sequencing 
or Gap-PCR 
Sample 
set 1 
Sample 
set 2 Primer set used 
for detection Probable phenotype (n=410) (n=342) (n=68) 
1. HBB:c.-151C>T 2 1 1* H1 β+ thalassaemia trait 
2. HBB:c.-138C>A 5 3 2* H1 β+ thalassaemia trait 
3. HBB:c.-138C>A; HBB:c.92+5G>C 1 1 0 H1+H3 β thalassaemia major 
4. HBB:c.-121C>T 1 1 0 H1 β+ thalassaemia trait 
5. HBB:c.17_18delCT 13 12 1 H2 βo thalassaemia trait 
6. HBB:c.17_18delCT; HBB:c.92+5G>C 1 1 0 H2+H3 β thalassaemia major 
7. HBB:c.19G>A 7 5 2 H2 Hb C trait 
8. HBB:c.19G>A; HBB:c.20A>T 1 0 1* H2 Hb SC disease 
9. HBB:c.20A>T (heterozygote) 24 21 3 H2 Hb S trait 
10. HBB:c.20A>T (homozygote) 18 18 0 H2 Sickle cell disease 
11. HBB:c.20A>T;HBB:c.92+5G>C 3 3 0 H2+H3 Sickle cell disease 
12. HBB:c.20A>T; 25 bp del 2 2 0 H2+H4 Sickle cell disease 
13. HBB:c.20A>T; HBB:c.176C>A 1 1 0 H2+H5 Hb S + Hb Sheffield 
14. HBB:c.20A>T; HBB:c.364G>C 2 2 0 H2+H7 Hb SD disease 
15. HBB:c.25_26delAA  3 3 0 H2 βo thalassaemia trait 
16. HBB:c.27_28insG  5 4 1* H2 βo thalassaemia trait 
17. HBB:c.33C>A; HBB:c.51delC  1 1 0 H2+H3 β thalassaemia major 
18. HBB:c.47G>A  6 4 2* H2+H3 βo thalassaemia trait 
19. HBB:c.67G>T 2 2 0 H3 βo thalassaemia trait 
20. HBB:c.79G>A 7 5 2 H3 Hb E trait 
21. HBB:c.79G>A; HBB:c.126_129delCTTT 2 1 1 H3+H4+H5 Hb E/βo thalassaemia 
22. HBB:c.92G>C (Hb Monroe); HBB:c.-92C>G  3 1 2* H1+H3 βo thalassaemia trait 
23. HBB:c.92+1G>A  16 12 4 H3 βo thalassaemia trait 
24. HBB:c.92+5G>C  96 82 14 H3 β+ thalassaemia trait 
25. HBB:c.92+6T>C  7 6 1* H3 β+ thalassaemia trait 
26. HBB:c.92+6T>C; HBB:c.93-21_96del 1 1 0 H3+H4 β thalassaemia major 
27. HBB:c.93-21_96del 35 27 8 H4 βo thalassaemia trait 
28. HBB:c.93-21G>A  18 11 7 H4 β+ thalassaemia trait 
29. HBB:c.112delT  1 1 0 H4 βo thalassaemia trait 
30. HBB:c.114G>A 1 1 0 H4 βo thalassaemia trait 
31. HBB:c.118C>T 16 13 3 H4 βo thalassaemia trait 
32. HBB:c.126_129delCTTT  2 2 0 H4+H5 βo thalassaemia trait 
33. HBB:c.135delC  14 10 4 H4+H5 βo thalassaemia trait 
34. HBB:c.140G>A 1 1 0 H4+H5 Hb K-Ibadan 
35. HBB:c.157G>C 1 1 0 H5 Hb Summer Hill 
36. HBB:c.250delG  6 6 0 H6 βo thalassaemia trait 
37. HBB:c.315+1G>A 14 10 4 H6 βo thalassaemia trait 
38. HBB:c.316-106G>C 1 1 0 H8 β+ thalassaemia trait 
39. HBB:c.316-3C>A  1 1 0 H8+H9 β+ thalassaemia trait 
40. HBB:c.321_322insG 1 1 0 H8+H9 βo thalassaemia trait 
41. HBB:c.364G>C 14 14 0 H9 Hb D Los Angeles 
42. HBB:c.316-149_*342delinsAAGTAGA 
(heterozygous) 
1 1 0 G2 βo thalassaemia trait 
43. HBB:c.316-149_*342delinsAAGTAGA (homozygous) 1 1 0 G2 β thalassaemia major 
44. NG_000007.3:g.66258_184734del118477 3 2 1 G1+G2 βo thalassaemia trait 
False positive by HRM - 1 0 1 Not applicable 
No mutation detected 49 44 4  - Not applicable 
See following page for table legend. 
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Legend for Table 18 
Samples were analysed by HRM-PCR either after (Sample set 1; n=342) or prior to (Sample set 
2; n=68) sequencing of the HBB gene. HRM-PCR correctly identified all samples with pathological 
sequence variations (n=355). Furthermore, it was possible to correctly assign a genotype based 
on the HRM-PCR data (Sample set 2) for all but 10 samples (indicated by *). GRACE-PCR 
correctly identified two known cases with 619 bp deletions and also identified a further three cases 
with deletions of both the promoter and third exon. Gap-PCR subsequently confirmed the 
presence of Filipino (118 kb) deletion for these three cases. 
Table from Turner et al. 2016 BMC Medical Genetics, 17:75 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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The CLCN7 gene was selected as a reference gene for GRACE-PCR. As 
previously described, the CLCN7 gene is well suited as a reference gene since it 
has no pseudo genes and defects in the gene result in an obvious phenotype 
(Fallah et al. 2010; Babashah et al. 2009). The G3 primer set was designed to 
target the CLCN7 gene and generate a product with a melting temperature 
approximately 8 oC lower that the products of the G1 and G2 primer sets. This 
resulted in GRACE-PCR melting curves with two distinct steps corresponding to 
the melting of the reference gene product and the HBB product (Figure 26). The 
drop of fluorescence as each product melts is proportional to the amount of the 
product present. Limiting the number of cycles to 26 ensured that the relative 
amounts of products remained proportional to the gene copy numbers. Thus, 
normalized melt curve data allowed the number of gene copies to be determined 
by simple visual analysis (Figure 26B). 
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Figure 26: GRACE-PCR to determine copy numbers of the HBB gene. Limited cycle GRACE-
PCR was used to amplify targets from the CLCN7 reference gene and the third exon of the HBB 
gene. The raw melt curves (A) are difficult to interpret, but after normalization (B) the ratio of 
CLCN7:HBB gene copy numbers is easily visualized. Figure from Turner et al. 2016 BMC Medical 
Genetics, 17:75 (Creative Commons Licence http://creativecommons.org/licenses/by/4.0/). 
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6.3.2 Initial assessment of the assay 
The assay was initially assessed using 342 samples for which the HBB gene had 
been previously sequenced and included two samples known to be positive for 
the 619 bp deletion. For 26 of these samples the assay did not yield the expected 
result, with 23 of these discrepancies due to interference from the common 
synonymous SNP HBB:c.9C>T, two due to deletions and one was an abnormal 
melt curve obtained with primer set H1. 
The initial version of the assay was not able to distinguish heterozygous Hb C 
(Table 18; Genotype 7, HBB:c.19G>A; n=5) from the heterozygous form of the 
common synonymous SNP HBB:c.9C>T (Figure 27B). Likewise, homozygous Hb 
S (Table 18; Genotype 10, HBB:c.20A>T; n=18) could not be distinguished 
reliably from the homozygous form of the HBB:c.9C>T SNP. This issue was 
resolved by the use of an unlabelled probe (Zhou et al. 2005; Hondow et al. 2011)  
designed to cover the HBB:c.19G>A and HBB:c.20A>T mutations, but not the 
nearby HBB:c.9C>T SNP (Figure 17 and Table 13). This approach resulted in 
clear separation of the pathological mutations in the probe melt region (Figure 
27C). Repeating the HRM-PCR analysis in the presence of the unlabelled probe 
for the 23 samples in which a mutation was initially missed, yielded results 
consistent with sequencing (Table 18; columns Sequencing versus Sample set 
1).  
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Figure 27: Representative unlabelled probe HRM-PCR difference plots. Addition of the 
unlabelled probe allows differentiation of the pathological HBB:c.19G>A heterozygotes from 
common non-pathological HBB:c.9C>T heterozygotes; and of HBB:c.20A>T homozygotes from 
HBB:c.9C>T homozygotes. The unlabelled probe produced distinct probe and amplicon melt 
regions (A). Certain pathological variants cannot be distinguished from the HBB:c.9C>T SNP in 
the amplicon melt region (B), but are clearly separated in the probe melt region (C). Figure from 
Turner et al. 2016 BMC Medical Genetics, 17:75 (Creative Commons Licence 
http://creativecommons.org/licenses/by/4.0/). 
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GRACE-PCR correctly detected the two samples known to be positive for the 619 
bp deletion as having deletions of the third exon of the HBB gene (Table 18, 
genotypes 42 and 43). GRACE-PCR also indicated that two additional samples 
had large deletions of the HBB gene involving both the promoter and the third 
exon. Both of these unexpected cases were subsequently confirmed by Gap-
PCR to be positive for the Filipino b-thalassaemia deletion 
NG_000007.3:g.66258_184734del118477 (Figure 28).   
After modifying the assay to include the probe and confirming the presence of the 
deletions, only one of the 342 samples in the initial assessment failed to give the 
expected result. This sample produced an abnormal melting curve with the H1 
primer set the first time it was tested. On retesting the sample was found to be 
wild type, this sample is listed as a false positive in Table 18.  
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Figure 28: Gap-PCR for the Filipino deletion (NG_000007.3:g.66258_184734del118477).  
PCR is performed with primers on either side of the deletion’s breakpoints. Two positive samples 
are shown, with the detection of a 920 base-pair product on 1% agarose gel indicating the 
presence of the deletion. 
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6.3.3 Validation of the assay 
An additional 68 samples without prior sequence information were analysed, 63 
samples had HRM melting curves that indicated the presence of sequence 
variations other than the common HBB:c.9C>T SNP, and for one sample 
GRACE-PCR indicated a gene deletion. For the remaining four samples, there 
was no evidence of a sequence change. It was noted that the HRM-PCR 
difference plots were highly reproducible between runs and between samples 
(Figure 25; panels A versus B). This raised the possibility that HRM-PCR could 
be used not only to detect sequence variations but also reveal the actual 
nucleotide change. For 53 of the 63 samples in which a sequence variation was 
detected, it was possible to assign a provisional genotype based only on the 
HRM-PCR data. Subsequent sequencing of the HBB gene confirmed that the 
four samples without variation by HRM-PCR had not contained any sequence 
changes, and that the 63 samples identified with variations all carried pathological 
mutations. The sample, which tested positive by GRACE-PCR, was confirmed by 
Gap-PCR to be another example of the Filipino β-thalassaemia deletion. 
Furthermore, all 53 of the provisional genotypes assigned by analysis of the 
HRM-PCR data were proved to be correct. The 10 samples, for which no 
provisional genotype could be assigned, were found to have genotypes that were 
either absent, or only present in a very few cases in the initial 342 samples (Table 
18; columns Sample set 2 versus Sample set 1). 
A combination of sequencing, Gap-PCR and the commercial b-globin StripAssay 
showed that 361 of the 410 samples included in the study contained one or more 
mutations in the HBB gene. The assay was able to detect all 361 abnormal 
samples and generated just one false positive result (Table 18; columns 
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Sequencing versus Sample sets 1&2). This equates to a sensitivity of 100.0% 
(95% confidence interval 98.7 - 100.0%) and a specificity of 98.0% (95% 
confidence interval 87.8 – 99.9%). In total, the 361 positive samples in the study 
accounted for 44 distinct pathological genotypes (Table 18). Examples of the 
HRM-PCR difference melt plots for each of the mutations detected are shown in 
Figures 29 to 32. Representative sequencing data for the mutations found are 
shown in Figures 33 to 36. 
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Figure 29: Examples of HBB gene mutation detected by HRM-PCR (part 1)  
(A) HBB:c.-151C>T; (B) HBB:c.-138C>A; (C) HBB:c.-121C>T ; (D) HBB:c.17_18delC; (E) 
HBB:c.19G>A; (F) HBB:c.19G>A probe melt; (G) HBB:c.20A>T ; (H) HBB:c.20A>T probe melt; 
(I) HBB:c.25_25delAA; (J) HBB:c.27_28insG. 
	 123	
 
Figure 30: Examples of each of the HBB gene mutation detected by HRM-PCR (part 2) 
(A) HBB:c.33c>A; (B) HBB:c.47G>A, primer set H2; (C) HBB:c.47G>A, primer set H3; (D) 
HBB:c.51delC; (E) HBB:c.67G>T; (F) HBB:c.79G>A; (G) HBB:c.92G>C; (H) HBB:c.92+1G>A;  
(I) HBB:c.92+5G>C; (J) HBB:c.92+6T>C.  
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Figure 31: Examples of each of the HBB gene mutation detected by HRM-PCR (part 3) 
(A) HBB:c.93-21G>A; (B) HBB:c.93-21_96del; (C) HBB:c.112delT; (D) HBB:c.114G>A; (E) 
HBB:c.118C>T; (F) HBB:c.126_129delCTTT, primer set H4; (G) HBB:c.126_129delCTTT, primer 
set H5; (H) HBB:c.135delC, primer set 4; (I) HBB:c.135delC, primer set H5; (J) HBB:c.140G>A, 
primer set H4.  
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Figure 32: Examples of each of the HBB gene mutation detected by HRM-PCR (part 4) 
(A) HBB:c.140G>A, primer set H5; (B) HBB:c.157G>C; (C) HBB:c.176C>A; (D) HBB:c.250delG; 
(E) HBB:c.315+1G>A; (F) HBB:c.316-106G>C; (G) HBB:c.316-3C>A, primer set H8; (H) 
HBB:c.316-3C>A, primer set H9; (I) HBB:c.321_322insG; (J) HBB:c.346G>C. 
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Figure 33: Representative sequencing data for mutations found by HRM-PCR (part 1) 
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Figure 34: Representative sequencing data for mutations found by HRM-PCR (part 2) 
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Figure 35: Representative sequencing data for mutations found by HRM-PCR (part 3) 
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Figure 36: Representative sequencing data for mutations found by HRM-PCR (part 4) 
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6.4 Discussion 
Quantification of Hb A2 is routinely used for the detection of b-thalassaemia 
carriers. The normal range for Hb A2 is 2.0–3.3% with levels above 3.5% being 
considered indicative of b-thalassaemia trait (Stephens et al. 2011). The current 
study included 22 samples with Hb A2 levels greater than 3.5%, which did not 
have detectable mutations or deletions of the HBB gene. This is in line with 
previous observations that false positive results can be a significant problem 
when screening for b-thalassaemia carriers based on Hb A2 levels (Giambona et 
al. 2008). Indeed, elevated Hb A2 in the absence of b-thalassaemia has recently 
been linked to mutations in the KLF1 gene (Perseu et al. 2011), suggesting that 
molecular confirmation may be required. In our laboratory, HBB gene mutations 
are routinely detected with a commercial reverse hybridization assay (ViennaLab 
Diagnostics). This commercial kit was designed to detect the 22 most prevalent 
mutations found in Indian and Middle Eastern populations. The current study 
identified 55 samples (13.4%) with mutations not targeted by this kit. This 
illustrates the limitations of conventional PCR techniques when screening for b-
thalassaemia trait in highly heterogeneous populations, and highlights the 
advantages of using a more universal assay, such as the one described here. 
The first application of HRM-PCR to the HBB gene was described by Wittwer et 
al. (2003). This was a small-scale study designed to detect the mutations 
responsible for the abnormal haemoglobins Hb S and Hb C (Wittwer et al. 2003). 
Despite the fact that they amplified approximately the same section of the gene 
covered by the H2 primer set in the current study, the authors did not report any 
problems with the HBB:c.9C>T SNP. This was presumably due to the relatively 
small number of samples tested (n=12). Similarly, a more recent study targeting 
	 131	
HBB gene mutations common in the Iranian population (Ramezanzadeh et al. 
2016) also amplified this section of the HBB gene and did not comment on any 
issues arising from SNP interference, however the number of samples was again 
small (n=20). In contrast, in the current study the HBB:c.9C>T SNP was 
encountered and it was not possible to resolve all genotypes without the addition 
of the unlabelled probe. An observation which illustrates the importance of 
adequate validation of HRM assays.  
Previous studies have described HRM-PCR assays to scan the HBB gene in 
different populations. Shih et al. (2009), Saetung et al. (2013), Lin et al. (2014), 
Prajantasen et al. (2015), and Chassanidis et al. (2016) used the technique to 
detect the most prevalent mutations in Taiwanese, Thai, Chinese and Greek 
populations respectively (Shih et al. 2009; Saetung et al. 2013; Lin et al. 2014; 
Prajantasen et al. 2015; Chassanidis et al. 2016). Three of these studies (Shih et 
al. 2009; Lin et al. 2014; Prajantasen et al. 2015) addressed the issue of the 
HBB:c.9C>T SNP by placing the primer over the SNP. The same approach or 
overlaying the SNP was also used in a simple single amplicon HRM-PCR assay 
designed to detect just the HBB:c.20A>T mutation (Yue et al. 2014). 
A possible concern with placing the primer over the SNP is that it might result in 
allele dropout, particularly if a SNP is located close to the 3’ end of a primer. The 
primers described by Shih et al. (2009) put the SNP close to the 3’ end, while the 
primers used by Lin et al. (2014) and Prajantasen et al. (2015) place the SNP in 
the middle of the primer where it is less likely to have a significant effect. 
However, the HBB:c.19G>A and HBB:c.20A>T mutations are located under the 
primers used by Lin et al. (2014) and Prajantasen et al. (2015), which would 
probably affect the amplification of these common and pathologically significant 
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alleles.  Since these mutations, which are rare in China (Zeng & Huang 2001) 
and Thailand (Tritipsombut et al. 2011), were not included in the specific 
mutations being targeted this would not have been a significant concern when 
screening these populations. However, these mutations are very common 
throughout Africa and the Middle East (Weatherall & Clegg 2001), thus the 
assays described by Lin et al. (2014) and Prajantasen et al. (2015) are not well 
suited for screening in these regions. In contrast to overlaying the HBB:c.9C>T 
SNP with a primer, the approach described here of using the unlabelled probe, 
allowed detection of all the mutations encountered in this area of the HBB gene.  
Saetung et al. (2013) avoided complications from the HBB:c9.C>T SNP by simply 
not scanning this region of the HBB gene. This approach limits the usefulness of 
their assay in populations where mutations in this area of the gene are common. 
Chassandis et al. (2016) also reported problems with the HBB:c.9C>T SNP which 
were addressed shortening the amplicon, since their validation did not include 
the HBB:c.19G>A mutation it is not clear if this approach would allow this 
mutation to be reliably differentiated from the SNP.  
Other high frequency SNPs also complicated HRM analysis of the HBB gene. 
These were HBB:c.315+16G>C (rs10768683) and HBB:c.316-185C>T 
(rs1609812).  We addressed this issue by substituting the respective SNP with 
inosine in each primer designed to cover these bases. This approach, as 
previously demonstrated for the Breast cancer early onset (BRCA1 and 
BRACA1) genes (Hondow et al. 2011), eliminated the detection of this high 
frequency SNP and provided clean HRM profiles (Figure 25; 1A and 1B).  
Until recently, deletions of the HBB gene were considered to be rare with only the 
619 base deletion being common, accounting for around 20% of b-thalassaemia 
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alleles in some parts of India and Pakistan (S. Thein 2005). However, it has now 
become apparent that HBB gene deletions are more frequent than was previously 
believed. The 3.4 kb deletion has a prevalence of up to 4% in some parts of 
Thailand (Prathomtanapong et al. 2009) and the Filipino b-thalassaemia deletion 
has been described as being a common cause of b-thalassaemia in Filipinos 
(Waye et al. 1994; Yamashiro et al. 2012). Indeed, it has been suggested that 
deletions involving the β-globin gene cluster account for as many as 10% of all 
b-thalassaemia mutations (Harteveld 2005). 
Conventional HRM-PCR works well for the detection of point mutations and small 
indels, but is not a useful technique for the detection of larger gene 
rearrangements. Melting curve assays have been described to detect the 3.4 kb 
deletion of the HBB gene (Prathomtanapong et al. 2009; Saetung et al. 2013). 
However, for other deletions Gap-PCR is still commonly used. Although Gap-
PCR is a simple and robust technique, it is not ideal for high volume screening, 
since the use of agarose gel electrophoresis for detection makes it a time 
consuming open tube technique.  An important limitation of both Gap-PCR and 
the existing melt curve assays is that they can only be used to detect specific 
deletions with well-defined breakpoints and consequently are not suitable for the 
detection of novel or rare deletions. In contrast, the GRACE-PCRs included in 
the current study determine the copy number ratio between the HBB gene and 
the reference gene. Thus, GRACE-PCR can be used to detect large 
rearrangements of the HBB gene without prior knowledge of the breakpoints. In 
order to maximise the number of deletions that could be detected two GRACE-
PCR reactions were used, one targeting the promoter and the other targeting the 
third exon.   
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Allele dropout due to a SNP within a priming site is a potential risk with any PCR 
based assay. The use of the probe and primers containing inosine in the current 
assay addressed this concern for the most common high frequency SNPs 
associated with the HBB gene. However, with 868 known pathological mutations 
of the HBB gene, as well as a number of non-pathological ones, it is inevitable 
that there are SNPs associated with most priming sites. The risk of 
misinterpretation due to allele dropout is significantly mitigated by the overlapping 
nature of the HRM amplicons and by the use of two GRACE-PCR reactions. 
Furthermore, the fact that no problems due to allele dropout were encountered in 
the 410 samples evaluated in the study indicated that the risk is indeed small. 
Nevertheless, it is recommended that the possibility of allele dropout be 
considered when results of the assay do not correlate with other laboratory 
findings or the clinical picture. 
The general purpose of gene scanning is to identify amplicons carrying variant 
sequences. The HRM-PCR profiles of the amplicons not only indicated the 
presence of a variation in the sequence, but also often allowed the identification 
of the exact nucleotide change. In the 68 blindly analysed samples all variant 
sequences were correctly detected. Furthermore, in 84% of these cases the 
melting curves were sufficiently distinctive for the correct genotype to be assigned 
prior to sequencing (Table 18; columns Sample set 2 versus Sample set 1). As 
more experience is gained with this assay, provisional direct genotyping of almost 
all samples may well be possible. The observed genotyping ability of HRM-PCR 
for the HBB gene contrasts favourably with denaturing HPLC (DHPLC) assays, 
as DHPLC may require either a two-step assay (Su et al. 2003), or repeating after 
spiking with control DNA from a known variant (Li et al. 2008). 
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 When a mutation occurred in overlapping amplicon regions (Figure 17) it was 
detected in both amplicons (Table 18). This provided additional information 
assisting in the assignment of the correct genotype. For example, a sample found 
to be positive with both primer sets H4 and H5 was likely to be either 
HBB:c.126_129delCTTT, HBB:c.135delC or HBB:c.140G>A, since they were the 
only mutations identified in the current study that occurred in this region of 
overlap. 
Interestingly, SNPs in linkage disequilibrium with pathological mutations also 
provide additional information and may assist in assigning the correct genotype. 
For example, an association between Hb Monroe (HBB:c.92G>C) and the SNP 
(HBB:c.-92C>G) in the HBB gene promoter has been reported (Fedorov et al. 
1993).  In the current study three cases of Hb Monroe in association with HBB:c.-
92C>G were found (Table 18; Genotype 22). The Hb Monroe mutation and the 
SNP resulted in distinctive melting curves in amplicons obtained with primer sets 
H3 and H1, respectively.  
No mutations were found in the region of the HBB gene scanned by primer sets 
H7, H10 and H11, indicating that mutations in this part of the gene are 
comparatively rare in the population studied (Table 18). It is interesting to note 
that even in the highly heterogeneous population of the UAE, 91% of positive 
cases could be detected using just 5 of the 13 primer sets. This suggests that a 
stepwise approach could be used starting with high mutation frequency 
amplicons and thus reducing the number of PCR reactions required to obtain 
results.  
The HRM-PCR / GRACE-PCR assay uses short amplicons, the longest being 
158 bp. Consequently, DNA of a quality suitable for routine molecular testing 
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should be adequate. Indeed, no problems due to DNA quality were encountered 
during the study despite some samples being subjected to several freeze thaw 
cycles during method development.  Since the HRM-PCR / GRACE-PCR assay 
depends on the ability to detect subtle changes in melting behaviour the methods 
used for DNA extraction and subsequent dilution are important. All samples 
should be extracted using the same method and the DNA concentration adjusted 
using the same diluent in order to avoid any changes in ionic strength, which 
would affect melting behaviour.  
At a minimum, a known wild type sample should be included in each batch of 
samples tested using the HRM-PCR / GRACE PCR assay. This provides a known 
normal melt curve and assists in the interpretation of the data. The need for 
positive controls is more debatable. In a workflow where HRM-PCR is used as 
an initial screen and positive samples are sequenced, positive controls are 
probably redundant. However, if the intention is to assign a presumptive genotype 
based on the melt curve appearance then the inclusion of suitable positive control 
samples in the batch is strongly recommended.   
In our laboratory, the consumables costs for scanning the HBB gene with the 
combined HRM-PCR / GRACE-PCR assay were approximately one eighth the 
cost of sequencing. Additionally, the hands-on time required for HRM-PCR / 
GRACE-PCR was less than one third of that needed for sequencing. Thus, a 
workflow that pre-screens samples by HRM-PCR / GRACE-PCR offers the 
potential for significant cost saving by eliminating the need to sequence negative 
samples. Also, confirmatory sequencing can be performed directly on just the 
positive HRM amplicon (Erali & Wittwer 2010), which is cheaper and faster than 
sequencing the entire HBB gene. Even in laboratories where full globin gene 
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sequencing is preferred to gene scanning for the detection of point mutations, 
GRACE-PCR is still of value since it allows the detection of large deletions of both 
the HBB gene and the a-globin genes (see section 4.3.1) which are not readily 
identified by sequencing.  
The consumable costs for HRM-PCR are slightly higher than for other gene 
scanning techniques such as DGGE or SSCP, since the use of shorter amplicons 
results in the need for more PCR reactions. However, this is more than offset by 
savings in labour; HRM-PCR requires no further hands-on time after the initial 
reaction setup, while DGGE or SSCP both require the use of polyacrylamide gel 
electrophoresis.  
In the current study, the samples were manually pipetted and processed in 
batches of 72 PCR reactions. Since both HRM-PCR and GRACE-PCR lend 
themselves to automation, robotic reaction setup is possible, and if a micro-titre 
plate based PCR system was used, up to 384 reactions could be run 
simultaneously on a single plate. Although different annealing temperatures were 
used, all the HRM-PCR primers will perform adequately at 55 oC, which would 
simplify batch processing if micro-titre plates were adopted. 
In conclusion, the current study has resulted in the development of a robust assay 
for the detection of pathological HBB gene mutations. The approaches used for 
handling the high frequency SNPs mean that the assay is universally applicable, 
rather than being population specific. The inclusion of GRACE-PCR targeting 
both the gene promoter and third exon means that the assay has the ability to 
detect a wide range of large deletions of the HBB gene. The assay has sensitivity 
and specificity comparable to sequencing and was able to detect all mutations in 
the samples tested. Furthermore, this assay can be run at a fraction of the cost 
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of a full sequencing approach as 84% of positive samples could be provisionally 
genotyped. The assay has provided useful data on the spectrum of HBB gene 
mutations in the highly heterogeneous population of the United Arab Emirates. In 
the future, it should be able to serve as a screening test for suspected b-
thalassaemia carriers and variant haemoglobins.  
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7.0 First report of Hb Fontainebleau (HBA2:c.64G>C) in the homozygous 
form or in combination with deletional and non-deletional alpha 
thalassaemia 
 
7.1 Introduction 
Correct identification of any haemoglobin variant detected during screening is 
important, both in order to be able to assess the clinical relevance and to ensure 
appropriate genetic counselling. The reference method for identifying variant 
haemoglobins is Sanger sequencing of the globin genes (Greene et al. 2015). 
However, not all laboratories engaged in haemoglobinopathy screening are 
equipped to perform Sanger sequencing. Furthermore, time and cost constraints 
mean that sequencing is normally reserved only for those cases that cannot be 
adequately assessed by simpler biochemical techniques.  
For well described variants, characteristics such as the appearance of the HPLC 
chromatogram, the electrophoretic mobility and the patient’s phenotype may be 
sufficient to allow presumptive identification without the need for sequencing 
(Greene et al. 2015). However, some rare haemoglobins have only been 
described in a handful of individuals and consequently, very limited information 
is available with regards to the biochemical characteristics and expected 
phenotype. In such cases additional data is of value, since it may assist workers 
in correctly interpreting screening test results should further examples be 
encountered. One such rare haemoglobin is the a-globin variant Hb 
Fontainebleau (HBA2:c.64G>C / p.Ala22Pro), which has been described in just 
ten individuals worldwide (Wajcman et al. 1989; Almeida et al. 2001; Upadhye et 
al. 2012; Kyrri et al. 2009; Brennan et al. 2009). 
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7.2 Samples and methods 
7.2.1 Samples 
Twelve cases with a distinctive abnormal peak on the HPLC chromatogram were 
identified from samples submitted to SKMC laboratory for haemoglobin analysis. 
Ten of the 12 cases were identified from samples submitted to SKMC laboratory 
for mandatory pre-marital screening. Two additional cases were identified from 
samples submitted for investigation of a possible haemoglobinopathy.  
 
7.2.2 Methods 
DNA extraction – see section 4.1 
Sequencing HBA1 and HBA2 genes – see sections 4.3.4 and 4.4 
Sequencing HBB gene – see sections 4.3.5 and 4.4 
α-Globin genotyping – see section 4.3.8 
 
Full blood counts (Sysmex XN9000) and haemoglobin analysis by cation 
exchange HPLC (Biorad Variant II) were performed in the as part of the routine 
work up of these specimens in the SKMC haematology laboratory. CE (Sebia 
Capillarys 2) data was provided by Tawam laboratory (Al Ain, UAE). 
 
7.3 Results 
Hb Fontainebleau appears as an abnormal peak with a retention time of 2.87 
minutes on the HPLC chromatogram (Figure 37A). With CE, Hb Fontainebleau is 
detected as an unknown peak in zone 11 (Figure 37B).  
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Figure 37: Representative Hb analysis results for Hb Fontainebleau. (A) Results obtained 
using the Variant II HPLC system (Bio-Rad Laboratories). (B) Results obtained using the 
Capillarys 2 CE system (Sebia). In both cases Hb Fontainebleau is indicated with an arrow. Figure 
from Turner et al 2014, Hemoglobin Vol 38 (3) pp 216-220, used with permission from the 
publisher (Taylor and Francis). 
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Sequencing of the HBA1, HBA2 and HBB genes confirmed that in all 12 cases 
were examples of the rare alpha variant Hb Fontainebleau (HBA2:c.64G>C), one 
of which was homozygous (Figure 38). No abnormalities of the HBB gene were 
detected.  
Ten of these cases were found during the pre-marital screening of 4,184 
individuals, indicating a prevalence of 0.239% for Hb Fontainebleau in the 
population of the United Arab Emirates. In four cases Hb Fontainebleau was co-
inherited with the common –a3.7 deletion and in one case it occurred in 
combination with the aPoly A2 allele.  
The genotypes of the 12 cases are summarized in Table 19. 
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Figure 38: Representative sequencing data for Hb Fontainebleau. (A) sequencing data is 
shown for case 1 who is homozygous for Hb Fontainebleau (HBA2:c.64G>C). The affected 
nucleotide is indicated at position 170 of the electropherogram. (B) Case 2 is heterozygous for Hb 
Fontainebleau. (C) The  aPoly A2 mutation (HBA2:c.*+94A>G) was also found in case 2. Figure from 
Turner et al 2014, Hemoglobin Vol 38 (3) pp 216-220, used with permission from the publisher 
(Taylor and Francis). 
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Table	19:	Genotype	and	phenotype	data	for	patients	with	Hb	Fontainebleau 
Case 
Hb 
Fontaine-
bleau (%) 
Hb 
A2 
(%) 
Hb 
F 
(%) 
Hb 
(g/L) 
Mean Cell 
Volume 
(fL) 
Red Blood 
Cells 
(x109 /L) 
Age 
(yrs) Sex Genotype 
1 36.7  1.0  0.2  124   (117-155) 74.0*  (81-100) 5.31*  (3.8-5.1) 27 F aFontainebleaua/aFontainebleaua 
2 31.2  0.8  2.7  108*  (110-140) 62.7*  (70-84) 5.64*  (3.8-4.8) 2 M aFontainebleaua/aPoly A2a 
3 22.9  1.5  1.0  143   (132-173) 71.2*  (80-99) 6.31*  (4.3-5.7) 23 M aFontainebleaua/a-3.7 
4 20.0  1.1  1.0  151   (126-174) 75.5 * (81-103) 6.40*  (3.8-5.8) 66 M aFontainebleaua/a-3.7 
5 14.8  1.4  0.3  77*    (117-155) 58.3*  (81-100) 5.32*  (3.8-5.1) 32 F aFontainebleaua/a-3.7 
6 22.7  1.3  0.1  121   (117-155) 74.7 * (81-100) 5.10  (3.8-5.1) 26 F aFontainebleaua/a-3.7 
7 15.0  1.7  0.1  146   (132-173) 83.1   (80-99) 5.49  (4.3-5.7) 39 M aFontainebleaua/aa 
8 14.0  1.6  0.6  153   (132-173) 83.7   (80-99) 5.70  (4.3-5.7) 32 M aFontainebleaua/aa 
9 14.3  1.5  0.2  139   (117-155) 75.0*  (81-100) 5.50*  (3.8-5.1) 35 F aFontainebleaua/aa 
10 15.3  1.5  0.0  146   (132-173) 80.9   (80-99) 5.44  (4.3-5.7) 30 M aFontainebleaua/aa 
11 12.5  1.5  0.1  105*  (117-155) 73.0*  (81-100) 4.82  (3.8-5.1) 23 F aFontainebleaua/aa 
12 15.0  2.1  0.1  144   (132-173) 83.7   (80-99) 5.45  (4.3-5.7) 27 M aFontainebleaua/aa 
	
The age and sex adjusted normal ranges are indicated in parenthesis. The Hb A2 in all twelve cases 
was below the normal range of 2.2-3.5%. The age adjusted normal range of Hb F was 1.3-5.0% for 
case 2 and 0.0-1.4% for all other cases; all samples fell within the normal range. *Indicates readings 
outside of the normal reference range for Hb, Mean Cell Volume and Red Blood Cell count. Table 
adapted from Turner et al 2014, Hemoglobin Vol 38 (3) pp 216-220, used with permission from the 
publisher (Taylor and Francis). 
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7.4 Discussion 
Hb Fontainebleau was first described in 1989 (Wajcman et al. 1989) in four family 
members of Italian descent. Subsequently, Hb Fontainebleau was identified in 
two individuals from the UK (Almeida et al. 2001), two from India (Upadhye et al. 
2012), one from Cyprus (Kyrri et al. 2009) and one man of Iraqi descent residing 
in New Zealand (Brennan et al. 2009). Hb Fontainebleau is caused by a single 
base change in the HBA1 or HBA2 gene 64 bases 3’ of the start of the initiation 
codon. The first round of amplification in the sequencing protocol generated PCR 
products specific for either the HBA1 or HBA2 gene. Consequently, it was 
possible to identify which a-globin gene contained the detected mutation. In all 
twelve cases presented here, the mutation giving rise to Hb Fontainebleau was 
found in the HBA2 gene. In previous studies of Hb Fontainebleau the variant 
haemoglobin was present in relatively high levels (25-28%) (Wajcman et al. 1989; 
Brennan et al. 2009). There is a general trend that higher levels of Hb 
Fontainebleau were observed in cases with a higher ratio of aFontainebleau genes to 
normal a-globin genes (Table 19). Case 1 was inferred to be homozygous for the 
Hb Fontainebleau mutation based on the sequencing data, the absence of any 
of the common deletional forms of a-thalassaemia and confirmation, by gene 
copy number analysis, that a normal number of a-globin genes were present. In 
this individual Hb Fontainebleau accounted for 36.7%, which was the highest 
level observed (Table 19).  
In case 2 the level of Hb Fontainebleau was 31.2%. This individual also inherited 
the aPoly A2 mutation (HBA2:c.*+94A>G), which results from a single base change 
94 bases 3’ from the stop codon in the transcription termination sequence of the 
HBA2 gene. The aPoly A2 mutation is sometimes referred to by the alternative 
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name aT Saudi. This is a severe non-deletional a-thalassaemia mutation, known to 
stop a-globin production from the HBA2 gene and also reduce the output of the 
downstream HBA1 gene (Thein et al. 1988). Consequently, production of normal 
a-globin chains would have been significantly reduced in this case, which was 
consistent with the comparatively high level of Hb Fontainebleau observed. This 
individual had mild anaemia, a significantly reduced MCV and a serum iron level 
of 5 µM indicating iron deficiency which may have contributed to these clinical 
findings. Mutations in the b-globin gene as a possible cause for the low MCV was 
excluded since no sequence variants were found in the b-globin gene in the 12 
cases investigated. 
Cases 3-6 were found to have Hb Fontainebleau in association with the common 
-a3.7 allele (Table 19). In cases 3, 4 and 6 the level of the variant haemoglobin 
ranged from 20.0 – 22.9%. Case 5 had the same genotype, but the level of Hb 
Fontainebleau was only 14.8%. However, this case was atypical, since there was 
clinically significant anaemia present and the MCV was much lower than in the 
other cases with the same genotype (58.3 fL versus 71.2-75.5 fL). No additional 
clinical history was available for case 5 that could help to explain the observed 
anaemia. The remaining six cases were all heterozygous for the Hb 
Fontainebleau mutation and did not have any additional a-globin defects. In these 
cases, the level of the haemoglobin variant ranged from 12.5 to 15.3%. 
Interestingly, this is somewhat lower than the levels previously reported of 25-
28% for the Italian family members (Wajcman et al. 1989) and 27.5% for the male 
of Iraqi decent (Brennan et al. 2009). The reasons for the observed difference in 
Hb Fontainebleau in the latter study (Brennan et al. 2009) are not clear. In the 
case of the Italian family this difference might be due to differences in 
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methodology or to the presence of hereditary spherocytosis (Wajcman et al. 
1989). It has previously been reported that the heterozygous form of Hb 
Fontainebleau in the absence of any other a-globin abnormality was associated 
with a reduced MCV in one male (Brennan et al. 2009). Our data did not support 
this observation, given that the MCV was normal in all four males with the 
aFontainebleaua/aa genotype (Table 19, cases 7, 8, 10, 12).  
All twelve cases had reduced Hb A2, suggesting that this is a common finding 
with Hb Fontainebleau. Previously, Hb A2 levels were only reported for two 
individuals with Hb Fontainebleau. One was in association with Hb S (Upadhye 
et al. 2012) and therefore was not directly comparable. The other was at the lower 
end of the normal range (Brennan et al. 2009). Interestingly, the small secondary 
peaks often seen in a-globin variants, due to the combination of the variant globin 
chain with normal d-globin chains or g-globin chains, were not observed when Hb 
Fontainebleau was detected by either HPLC or CE (Figure 37). However, there 
is a small elevation in the baseline to the right of the Hb A2 peak in the HPLC 
chromatogram, which is suggestive of a secondary peak at the lower limit of 
resolution. This may be the result of Hb Fontainebleau globin chains combining 
with normal d-globin chains to form Hb A2 Fontainebleau. 
The observed prevalence of Hb Fontainebleau was 0.239% (95% confidence 
interval 0.115-0.440), which was significantly higher than the prevalence of 
0.0005% (95% confidence interval 0.0001-0.0018; 2 cases out of 413,712) 
derived from published neonatal screening data in the UK (Almeida et al. 2001) 
and 0.0015% (95% confidence interval 0.00004-0.00838; 1 case in 65,668) from 
the screening program in Cyprus (Kyrri et al. 2009). Some caution is required 
when comparing statistics calculated from premarital studies with data from 
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neonatal screening. Nevertheless, the identification of twelve cases of this rare 
haemoglobin suggests that Hb Fontainebleau is a comparatively common a-
globin variant in the United Arab Emirates. It is likely that Hb Fontainebleau has 
been under reported in the past, since it is not detected by gel electrophoresis, 
having the same mobility as Hb A under both alkaline and acid conditions. Indeed, 
subsequent to the publication of the cases described above, a further four cases 
of Hb Fontainebleau have been described suggesting that this variant may be 
more common than was previously supposed (Purohit et al. 2014; Khosravi et al. 
2015; Rodríguez-Capote et al. 2015; Canatan et al. 2016). Hb Fontainebleau is 
readily detected by HPLC or CE and should be considered as a possible 
explanation if results similar to those shown in Figure 37 are encountered during 
haemoglobinopathy screening.  
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8.0 Detection of Hb Handsworth (HBA2:c.55G>C) inherited alone or in 
combination with Hb S (HBB:c.20A>T) and the -a3.7 alpha globin gene 
deletion in infants and children 
 
8.1 Introduction 
Hb S is a common pathological variant haemoglobin that is highly prevalent 
throughout Africa and the Middle East (Modell 2008). Heterozygous carriers of 
Hb S are largely asymptomatic (Habara & Steinberg 2016). However, when 
inherited in the homozygous state, or in combination with other 
haemoglobinopathies, Hb S may result in “one of the most lethal genetic 
diseases” (United Nations 2009) (Table 8 and section 2.3.2.2). Consequently, 
accurate diagnosis of Hb S carriers is essential for premarital genetic counselling.  
Indeed, the observation that 52% of couples identified as at risk by premarital 
screening opted to cancel the wedding illustrates that the results of screening 
tests have a profound impact on people lives (Memish & Saeedi 2011).  
Haemoglobinopathy screening is normally performed by HPLC or CE. In this 
context, otherwise benign haemoglobin variants which behave in a similar 
manner to Hb S are of significance since they could potentially lead to a 
misdiagnosis of Hb S and result in inappropriate genetic counselling (Joutovsky 
2004). One such variant is Hb Handsworth (Moradkhani et al. 2013; Zadjali et al. 
2014) (HBA1:c.55G>C or HBA2:c.55G>C).  
Information on Hb Handsworth is limited, since this variant has previously been 
reported in just ten individuals worldwide (Griffiths et al. 1977; Liang et al. 1981; 
Al-Awamy et al. 1985; Kyrri et al. 2009; Akbari & Hamid 2012; van Zwieten et al. 
2014; Zadjali et al. 2014). Furthermore, there are no reported cases of Hb 
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Handsworth being co-inherited with either Hb S or with a-globin gene deletions. 
Consequently, additional data on the behaviour of Hb Handworth and how it can 
be differentiated from the more pathological Hb S is of potential value to any 
worker interpreting haemoglobin screening data.  
 
8.2 Samples and methods 
8.2.1 Samples 
Samples were submitted to SKMC laboratory for investigation of a possible 
haemoglobinopathy. 
  
8.2.2 Methods 
DNA extraction – see section 4.1 
Sequencing HBA1 and HBA2 genes – see sections 4.3.4 and 4.4 
Sequencing HBB gene – see sections 4.3.5 and 4.4 
a-Globin genotyping – see section 4.3.8 
Full blood counts (Sysmex XN9000), haemoglobin analysis by HPLC (Biorad 
Variant II) and SICKLDEX solubility testing were performed in the as part of the 
routine work up of these specimens in SKMC haematology laboratory. CE (Sebia 
Capillarys 2) data was provided by Tawam laboratory.  
 
8.3 Results 
Genotypic and phenotypic data for the five cases of Hb Handsworth are 
summarised in Table 20. 
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Table 20: Phenotypic data and genotypes of the five patients with Hb 
Handsworth. 
 
 
Age and sex adjusted normal ranges are indicated in parenthesis. MCV: mean cell volume; 
RBC: red cell count. 
(a) For Case 2 the close proximity of the Hb Handsworth and Hb S peaks resulted in 
the instrument quantifying both peaks together.  
(b) Abnormal peaks presumed to be due to the combination of aHandsworth and bS globin.  
(c) Abnormal peak presumed to be due to the combination of aHandsworth and g globin.  
 
Parameter Case 1 Case 2 Case 3 Case 4 Case 5 
Sex-Age M – 9 yrs M – 12 yrs M – 2 yrs F – 37 yrs M - 6 wks 
Hb (g/L) 125 (115-145) 72 (120-150) 107 (110-140) 129 (117-155) 107 (107-171) 
MCV (fL) 76 (76-90) 52 (77-94) 59 (73-85) 72.4 (81-100) 82 (91-112) 
RBC (x1012/L) 5.07 (3.9-5.1) 5.14 (4.1-5.2) 5.70 (3.80-4.80) 5.18 (3.80-5.10) 3.80 (3.30-5.30) 
Hb F (%) 0.2 (0.0-1.4) 0.2 (0.0-1.4) 0.3 (0.0-1.0) 0.1 (0.0-1.4) 41.4 (45.7-67.3) 
Hb A2 (%) 2.7 (2.2-3.5) 3.2 (2.2-3.5) 4.1 (2.2-3.5) 3.7 (2.2-3.5) 0.4 (0.5-1.1) 
Hb S (%) Not present 
17.5(a) 
16 22 Not present 
Hb Handsworth (%) 15.1 11.7 6.9 11.9 
Other Hb Peaks (%) Not present 6.1(b) 7(b) 6.9(b) 22.7(c) 
Solubility test Negative Positive Positive Positive Negative 
Serum iron (mmol/L) 26.3 (5.8-34.5) 4.6 (5.8-34.5) 6.2 (11.0-21.0) Not tested Not tested 
Ethnicity Sudanese Sudanese Unknown Ethiopian Unknown 
Sequencing result 
HBA1 – wild type 
HBA2:c.55G>C;  
HBB- wild type 
HBA1 – wild type 
HBA2:c.55G>C;  
HBB:c.20A>T 
HBA1 – wild type 
HBA2:c.55G>C 
HBB:c.20A>T 
HBA1 – wild type 
HBA2:c.55G>C 
HBB:c.20A>T 
HBA1 – wild type 
HBA2:c.55G>C 
HBB – wild type 
a-globin StripAssay 
No a-globin 
gene deletion 
detected 
No a-globin 
gene deletion 
detected 
Heterozygous 
for -a3.7 deletion 
No a-globin 
gene deletion 
detected 
No a-globin 
gene deletion 
detected 
Genotype a
Handswortha/aa 
b/b  
aHandswortha/aa 
bS/b 
aHandswortha/-a3.7  
bS/b 
aHandswortha/aa 
bS/b 
aHandswortha/aa 
b/b 
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8.3.1 Detection of Hb Handsworth in an older child 
Case 1 was a nine years old boy, referred along with an older sibling for 
investigation of a possible haemoglobinopathy. Although the blood count was 
normal (Table 20), haemoglobin analysis revealed an abnormal peak on the 
HPLC chromatogram in the “S window” which was similar to chromatograms 
usually obtained for patients with sickle cell trait (Figure 39A versus 39B). Careful 
examination of the HPLC chromatogram revealed that despite being classified as 
probable Hb S by the analyser software, the retention time of the abnormal peak 
was slightly longer than for Hb S (Figure 39A versus 39B). Also, there was an 
additional very small peak (Figure 39A; Peak Z), possibly corresponding to the 
combination of aHandsworth and d globin chains, which is not seen in Hb S 
chromatograms (Figure 39B). The abnormal haemoglobin accounted for only 
15.1% of the total haemoglobin, which was somewhat lower than would be 
expected for sickle cell carriers. Furthermore, this boy’s older sibling was also 
investigated for a possible haemoglobinopathy and a highly unusual HPLC 
chromatogram was obtained (Figure 39C). These observations indicated that 
there was a haemoglobinopathy other than Hb S within the family and prompted 
molecular testing on both siblings. Sequencing of the a-globin genes showed that 
Case 1 was heterozygous for Hb Handsworth (HBA2:c55G>C). No other 
abnormalities of the globin genes were detected in this individual (Table 20, 
Figure 40). 
 
 
 
	 153	
8.3.2 Detection of Hb Handsworth when co-inherited with Hb S and an a-
globin gene deletion 
Sequencing of the globin genes showed that Case 2 (the older male sibling of 
Case 1) co-inherited the mutations for both Hb S (HBB:c.20A>T) and Hb 
Handsworth (HBA2:c.55G>C), a combination that has not been previously 
reported. The patient had significant anaemia (Hb = 72 g/L) and marked 
microcytosis (MCV = 52 fL). The HPLC chromatogram for Case 2 was highly 
distinctive with multiple abnormal peaks (Figure 39C). The retention time of Hb 
Handsworth (Figure 39C; Peak H) was very similar to that of Hb S (Figure 39C, 
Peak S) and resulted in a double peak. Additionally, two abnormal peaks were 
also detected (Figure 39C; Peaks X and Z) which are likely to correspond to the 
combination of aHandsworth & bS and aHandsworth & d globin chains respectively.  
Two further cases with HPLC chromatograms very similar to the one shown in 
Figure 39C were also identified in other unrelated patients referred for 
haemoglobin analysis (Cases 3 and 4 Table 20). Blood counts for both cases 3 
and 4 showed a reduced MCV, additionally case 3 was mildly anaemic (Table 
20). Sequencing confirmed that cases 3 and 4 were additional examples of Hb 
Handsworth (HBA2:c.55G>C) co-inherited with Hb S (HBB:c.20A>T). Case 3 was 
also positive for the common -a3.7 deletion; Hb Handsworth has not been 
previously reported in combination with an a-globin gene deletion. 
 
8.3.3 Detection of Hb Handsworth in an infant 
Case 5 was a six weeks old male infant who presented with a reduced MCV of 
82 fL (Table 20), the blood count was otherwise normal. Haemoglobin analysis 
by HPLC resulted in an unusual chromatogram showing three abnormal peaks 
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(Figure 41A). Subsequent sequencing of the globin genes showed that this case 
was an example of a simple Hb Handsworth heterozygote. The appearance of 
the HPLC chromatogram was very different from that obtained for Case 1, an 
older Hb Handsworth heterozygote (Figure 41A versus Figure 39A) or for an 
infant with Hb S (Figure 41A versus 41B). In addition to Hb Handsworth (Figure 
41A; Peak H), there was another major peak appearing with retention time 3.12 
min (Figure 41A; Peak Y). Similar to Case 1, the small peak Z adjacent to peak 
H was also present (Figure 41A). In contrast, both peaks Y and Z were absent 
on the HPLC chromatogram of the infant with sickle cell trait (Figure 41B).  
Analysis by CE shows that Hb Handsworth appeared in the Hb S zone and was 
consequently incorrectly identified by the software as Hb S (Figure 41C; Peak H). 
The second abnormal peak has the same mobility as Hb A2 (Figure 41C; Peak 
Y). 
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Figure 39: Haemoglobin analysis of Hb Handsworth and Hb S by HPLC using the Bio-Rad 
Variant II system. (A) Case 1 was a heterozygote for Hb Handsworth, a benign variant that it is 
important to distinguish from the far more clinically significant Hb S. (B) A typical HPLC pattern 
for a heterozygote Hb S, which can be differentiated from Hb Handsworth by the slightly shorter 
retention time and the absence of the Z peak. (C) Case 2, co-inherited Hb Handsworth and Hb S. 
Peaks for Hb Handsworth (H), Hb S (S), foetal haemoglobin (F) and haemoglobin A2 (A2) are 
indicated. The abnormal peak (X) is likely to correspond to the combination of aHandsworth with bS 
globin. A small peak (Z) appeared on the chromatogram of Hb Handsworth (Panels A and C), but 
was absent from Hb S (Panel B), making it a useful diagnostic feature.  
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Figure 40: Representative sequencing data for Hb Handsworth and Hb S. Sequence data 
showing the mutations associated with (A) Hb Handsworth (HBA2:c.55G>C) and (B) Hb S 
(HBB:c.20A>T)  in Case 2 who is heterozygous for both variants. Affected nucleotides are 
highlighted with red boxes. 
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Figure 41: Haemoglobin analysis of Case 5 (six weeks old neonate). (A) HPLC shows, in 
addition to Hb Handsworth (peak H) two additional abnormal peaks (Y and Z). The chromatogram 
for Case 5 is clearly distinct from that of an infant with sickle cell trait (B), which lacks peaks Y 
and Z. Analysis of Case 5 by CE is shown (C), with Hb Handsworth being misidentified as Hb S, 
the Y peak has the same mobility as Hb A2 and there is no indication of peak Z. 
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8.4 Discussion 
The most commonly used techniques to screen for haemoglobinopathies are 
HPLC and CE. When screening by HPLC, Hb Handsworth appears in the “S 
window” with a retention time very close to that of Hb S (Figure 39A versus 39B). 
Similarly, when testing by CE, Hb Handsworth has the same mobility as Hb S 
(Figure 41C). Consequently, it is easy to misdiagnose cases of Hb Handsworth 
as the far more pathological Hb S. Where such a mistake to occur, it would lead 
to a patient receiving inappropriate genetic counselling, which may have a 
profound impact on the choices made with regards to marriage and reproduction. 
The problem of differentiating Hb Handsworth from Hb S is further complicated 
by the fact that the two haemoglobins have similar mobility by both alkaline and 
acid gel electrophoresis (Zadjali et al. 2014). The sickle cell solubility test is 
cheap, easy to perform and may be of use in distinguishing Hb S from Hb 
Handsworth. However, as noted by the manufacturer, the sickle cell solubility test 
has a number of limitations that may give rise to either false positive or false 
negative results. Definitive differentiation of Hb Handsworth from Hb S requires 
the use of specialised techniques such as reversed phase high performance 
liquid chromatography (Wajcman et al. 2002), or molecular methods. Indeed, 
Case 1 could potentially be misdiagnosed as Hb S based on the HPLC result 
alone. This case was further investigated because an abnormal chromatogram 
was obtained for his sibling indicating the presence of more than one abnormality 
within the globin genes in his family.  
Our data show that when Hb Handsworth occurred in conjunction with Hb S it 
resulted in a characteristic HPLC chromatogram with four abnormal peaks 
(Figure 39C, Peaks S, H, Z and X). Distinctive chromatograms with multiple 
	 159	
abnormal peaks have also been reported for other a-globin variants in 
association with Hb S including Hb G-Honolulu (Paleari et al. 2012), Hb G-
Philadelphia (Moradkhani et al. 2013) and Q-India (Parab et al. 2015). Likewise, 
when Hb Handsworth occurred in the presence of a significant amount of Hb F, 
it resulted in a characteristic HPLC chromatogram with an additional abnormal 
peak (Figure 41; Peak Y). This result is similar to a previously described 
chromatogram obtained from a cord blood sample (Zadjali et al. 2014). However, 
in the single example presented here, where Hb Handsworth was found in the 
absence of Hb S or Hb F, the chromatogram could easily be mistaken for a sickle 
cell trait. While the level of abnormal haemoglobin was only 15.1%, which is less 
than would normally be expected in sickle cell trait (AlHamdan et al. 2007), it was 
consistent with the levels found in some Hb S variants, such as Hb S-Oman 
(Nagel et al. 1998) and also with the levels reported when Hb S is co-inherited 
with a duplication of the HBB gene (Shooter et al. 2015). Furthermore, in some 
patients the levels of Hb Handsworth in excess of 30% have been reported, 
(Griffiths et al. 1977; Zadjali et al. 2014) which increases the risk of confusion 
with Hb S.  
As mentioned above, levels of Hb Handsworth in heterozygotes are variable 
ranging from 11% to 33% (Griffiths et al. 1977; Zadjali et al. 2014). It has been 
postulated that levels may depend on whether the mutation is located in the HBA1 
or HBA2 gene, with the higher levels of the abnormal haemoglobin being 
associated with the HBA2 gene (Zadjali et al. 2014). The current study data do 
not seem to support this hypothesis, since the level Hb Handsworth was not 
particularly high (15.1 %) in Case 1, who had a mutation in the HBA2 gene. All 
the other four cases of Hb Handsworth presented here also carried a mutation in 
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the HBA2 gene (HBA2:c.55G>C), but the level of Hb Handsworth cannot be 
directly compared with that of previously described cases due to the interactions 
with Hb S and Hb F. 
During the current investigation Case 2 was the first example of Hb Handsworth 
found in association with Hb S. The patient had significant anaemia (Hb 72 g/L) 
and marked microcytosis (MCV 52 fL). These findings could not be explained by 
the mild iron deficiency (Table 20) and raised the possibility that the combination 
of these two abnormal haemoglobins might result in a clinically significant 
haemoglobinopathy. However, the subsequent identification of Cases 3 & 4 with 
very mild or no anaemia respectively, indicated that the clinical significance of the 
combination of Hb Handsworth and Hb S is unclear and that evaluation of 
additional cases is required. 
The difficulty to readily differentiate Hb Handsworth from Hb S by the most 
commonly used biochemical techniques (HPLC, CE, agarose gel 
electrophoresis) raises the possibility that this variant has been misdiagnosed 
with some cases being reported as sickle cell trait. If such a mistake was to occur, 
it could have significant consequences for pre-marital screening or genetic 
counselling. Consequently, Hb Handsworth represents a challenge when 
screening for haemoglobinopathies, which further underpins the need to confirm 
cases of suspected Hb S by alternative techniques and indicates that molecular 
testing is appropriate where a negative solubility test result is obtained.  
In agreement with a recent study (Zadjali et al. 2014), our data suggest that 
comparison of neonatal / infant testing results alongside samples obtained in later 
life is useful to discriminate between Hb S and Hb Handsworth. The HPLC result 
presented here (Figure 41A) is almost identical to those previously reported for a 
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new-born heterozygote Hb Handsworth patient (Zadjali et al. 2014). The extra 
HPLC peak at 3.12 min (Figure 41A, Peak Y) was reported to correspond to 
a2Handsworthg2 (Zadjali et al. 2014).  
There is also a very small peak close to peak H in all samples carrying the Hb 
Handsworth mutation (Figure 39A, 39C and 41A Peak Z), possibly corresponding 
to a2Handsworthd2 (Zadjali et al. 2014). Peak Z consistently appeared alongside peak 
H, but was never observed with peak S. Therefore, this small peak in combination 
with the slightly longer retention time can be used to differentiate Hb Handsworth 
from Hb S, providing the HPLC chromatograms are carefully analysed. The 
characteristic chromatograms presented here can be used as references to 
identify further Hb Handsworth cases, and they should alert laboratory 
investigators and clinicians to the presence of an a-variant. These findings may 
improve the recognition of this rare Hb variant, thus reducing the risk of 
misdiagnosis and incorrect genetic counselling.  
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9.0 Conclusion 
In a paper published in 1974 Arno Motulsky the “father of pharmacogenetics” 
noted that, in genetics “Many fundamental concepts have become clarified by 
investigations on human haemoglobins” (Motulsky 1974); a comment recently 
described as prescient (Orkin 2016), since it predated both the earliest molecular 
characterisation of a thalassaemia mutation (Orkin et al. 1979) and the period of 
intense study of the globin genes which followed. As a result of these ongoing 
efforts more that 1,700 mutations affecting the function of the globin genes have 
now been described (Hbvar 2017); a level of diversity that significantly 
complicates molecular diagnostics. Nevertheless, a combination of Sanger 
sequencing of the globin genes to detect point mutations and MLPA for larger 
gene rearrangements will allow the definitive diagnosis of vast majority of 
haemoglobinopathies. However, these techniques are too expensive and 
complex to be used for high volume screening. Consequently, the primary 
problem facing clinical laboratories is not so much accurate diagnosis of these 
conditions, as cost effective accurate diagnosis. For this reason, relatively simple 
PCR based techniques are likely to remain the main stay of haemoglobinopathy 
molecular testing for some time to come. In this context, the assays developed 
during the current study are attractive because they offer possible savings in 
labour and reagents.  
There are three main challenges in the accurate diagnosis of 
haemoglobinopathies, the detection of large gene deletions / duplications, the 
detection thalassaemia causing point mutations / indels and the identification of 
abnormal haemoglobins. 
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Deletions of the globin genes are by far the most common cause of a-
thalassaemia and a somewhat less frequent, but still important, cause of b-
thalassaemia. Gap-PCR is a simple and robust technique that has been widely 
used for the detection of globin gene deletions for the past 20 years. However, 
despite its continuing popularity, Gap-PCR has a number of disadvantages, it is 
time consuming, relatively labour intensive, not easily automated and being an 
open tube technique there is a risk of amplicon contamination. Consequently, 
Gap-PCR is not particularly well suited to high volume screening. In contrast 
GRACE-PCR is faster, less labour intensive and could be readily automated, 
making it ideal for high throughput screening. 
Sanger sequencing remains the “gold standard” for the detection point mutations 
/ indels, which account for the majority of b-thalassaemia alleles. Although 
improvements in the technology have greatly simplified Sanger Sequencing, the 
technique is still relatively complex and expensive. Gene scanning is a popular 
alternative approach and in recent years HRM-PCR has become the preferred 
scanning technology, since it eliminates the need for post amplification 
processing by electrophoresis or chromatography. When combined with GRACE-
PCR, the HRM assay developed in the current study allows the theoretical 
detection of 97% of all described pathological mutations of the HBB gene. Thus, 
the assay offers coverage that compares very favourably to other currently used 
techniques. Due to an inability to detect large deletions, Sanger sequencing of 
the HBB gene offers only 95% coverage of mutations, while previously described 
HRM-PCR assays have very limited ability to detect deletions and typically do not 
scan the entire gene. As a result of these limitations, these assays would 
theoretically detect 35%-90% of mutations listed in the HbVar database (Shih et 
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al. 2009; Saetung et al. 2013; Lin et al. 2014). The value of including a GRACE-
PCR component in the HBB gene scanning assay is illustrated by the 
identification of three cases of the Filipino deletion, a mutation not previously 
reported in the UAE.   
Most variant haemoglobins are readily detected by haemoglobin analysis using 
HPLC or CE, but can be difficult to correctly identify without sequencing, 
particularly if the behaviour of the variant is not well described. The information 
presented here on Hb Fontainebleau and Hb Handsworth should assist in the 
correct identification of these variants and in the case of Hb Handsworth may 
avoid confusion with the more clinically significant Hb S.  
The molecular diagnosis of haemoglobinopathies has evolved rapidly in recent 
years. Using modern techniques, patient workups that once took weeks can now 
be accomplished in just a few hours. As molecular testing migrates from specialist 
centres to routine diagnostic laboratories, there is a growing need for simple cost-
effective assays that are well suited to high throughput screening such as the 
ones developed in this study.  
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10.0 List of abbreviations 
2,3 DPG 2,3 Diphosphoglycerate 
AHSP Alpha haemoglobin stabilizing protein 
APC Adenomatous polyposis gene 
ARMS Amplification Refractory Mutation System 
ASO Allele specific oligonucleotide 
ATM Ataxia telangiectasia mutated serine / threonine kinase gene 
BCL11A  B cell CLL / lymphoma 11A gene  
BLAST  Basic Logical Alignment Tool 
BRACA1  Breast cancer 1, early onset gene 
BRACA2  Breast cancer 2, early onset gene 
CE  Capillary electrophoresis 
CLCN7  Chloride channel voltage sensitive 7 gene 
DGGE  Denaturing gradient gel electrophoresis 
DHPLC  Denaturing high performance liquid chromatography 
DMD  Dystrophin gene 
DMNT1  DNA Methyltranferase 1 
dNTP  Deoxynucleoside triphosphate 
DR  Direct repeat 
DRED  Direct repeat erythroid-definitive 
EDTA  Ethylenediaminetetraacetic acid 
EPO  Erythropoietin  
FOG1  Friend of GATA1 
GATA1  GATA binding protein 1 
GDF15  Growth differentiation factor 15 
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GNU  GNU is not UNIX 
GRACE  Gene ratio assay copy enumeration 
Hb A Haemoglobin A 
HBA1 Haemoglobin subunit alpha 1 gene 
Hb A2 Haemoglobin A2 
HBA2 Haemoglobin subunit alpha 2 gene 
HBB Haemoglobin subunit beta gene 
Hb C Haemoglobin C 
Hb D Haemoglobin D 
HBD Haemoglobin subunit delta gene 
Hb E Haemoglobin E 
HBE1 Haemoglobin subunit epsilon 1 gene 
Hb F Haemoglobin F (Foetal haemoglobin) 
HBG1 Haemoglobin subunit gamma 1 gene 
HBG2 Haemoglobin subunit gamma 2 gene  
Hb H Haemoglobin H 
HBQ1 Haemoglobin subunit theta 1 gene 
Hb S Haemoglobin S 
HBS1L HBS1 like translational GPTase gene 
HBZ Haemoglobin subunit zeta gene 
HGNC HUGO gene nomenclature committee 
HIV Human immunodeficiency virus 
HPFH Hereditary persistence of foetal haemoglobin 
HPLC High performance liquid chromatography 
HRM High resolution melting 
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HSP70 Heat shock protein 70 
HUGO Human genome organization 
INDEL Insertion / deletion 
IVS Intervening sequence 
KLF1 Krupple like factor 1 gene 
LCR Locus control region 
LSD1 Lysine specific histone demythylase 
MAF Minor allele frequency 
MCS Multi-species conserved sequence 
MCV Mean cell volume 
MLPA Multiplex ligation-dependent probe assay 
MYB MYB proto-oncogene 
NCBI National centre of biotechnology information 
NR2C1 Nuclear receptor subfamily 2 group C member 1 gene 
NR2C2 Nuclear receptor subfamily 2 group C member 2 gene 
NTDT Non-transfusion dependent thalassaemia 
NuRD Nucleosome remodelling deacetylase complex  
PCR Polymerase chain reaction 
pO2 Partial pressure of oxygen (tissue tension) 
PTEN Phosphate and tensin homolog gene 
PTO Phosphorothioate 
qPCR Quantitative polymerase chain reaction 
QTL Quantitative trait loci 
SCD Sickle cell disease 
SKMC Sheikh Khalifa Medical City 
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SNP Single nucleotide polymorphism 
SSCP Single strand chain polymorphism 
TAL1 T cell acute lymphocytic leukaemia 1 
TR2 Testicular receptor 2 
TR4 Testicular receptor 4 
TWSGI Twisted gastrulation factor 
UAE United Arab Emirates 
UTR Untranscribed region 
WHO World Health Organization 
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